0001360214 2020-01-01 2020-09-30 0001360214 2020-11-06 0001360214 2020-09-30 0001360214 2019-12-31 0001360214 HROW:SurfaceOphthalmicsMember 2020-09-30 0001360214 HROW:SurfaceOphthalmicsMember 2019-12-31 0001360214 HROW:MeltPharmaceuticalsMember 2020-09-30 0001360214 HROW:MeltPharmaceuticalsMember 2019-12-31 0001360214 2020-07-01 2020-09-30 0001360214 2019-07-01 2019-09-30 0001360214 2019-01-01 2019-09-30 0001360214 HROW:ProductSalesNetMember 2020-07-01 2020-09-30 0001360214 HROW:ProductSalesNetMember 2019-07-01 2019-09-30 0001360214 HROW:ProductSalesNetMember 2020-01-01 2020-09-30 0001360214 HROW:ProductSalesNetMember 2019-01-01 2019-09-30 0001360214 HROW:OtherRevenuesMember 2020-07-01 2020-09-30 0001360214 HROW:OtherRevenuesMember 2019-07-01 2019-09-30 0001360214 HROW:OtherRevenuesMember 2020-01-01 2020-09-30 0001360214 HROW:OtherRevenuesMember 2019-01-01 2019-09-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-07-01 2020-09-30 0001360214 HROW:MeltPharmaceuticalsMember 2019-07-01 2019-09-30 0001360214 HROW:MeltPharmaceuticalsMember 2020-01-01 2020-09-30 0001360214 HROW:MeltPharmaceuticalsMember 2019-01-01 2019-09-30 0001360214 HROW:SurfaceOphthalmicsMember 2020-07-01 2020-09-30 0001360214 HROW:SurfaceOphthalmicsMember 2019-07-01 2019-09-30 0001360214 HROW:SurfaceOphthalmicsMember 2020-01-01 2020-09-30 0001360214 HROW:SurfaceOphthalmicsMember 2019-01-01 2019-09-30 0001360214 HROW:EtonPharmaceuticalsMember 2020-07-01 2020-09-30 0001360214 HROW:EtonPharmaceuticalsMember 2019-07-01 2019-09-30 0001360214 HROW:EtonPharmaceuticalsMember 2020-01-01 2020-09-30 0001360214 HROW:EtonPharmaceuticalsMember 2019-01-01 2019-09-30 0001360214 us-gaap:CommonStockMember 2019-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001360214 us-gaap:RetainedEarningsMember 2019-06-30 0001360214 us-gaap:ParentMember 2019-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-06-30 0001360214 2019-06-30 0001360214 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001360214 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001360214 us-gaap:ParentMember 2019-07-01 2019-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0001360214 us-gaap:CommonStockMember 2019-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001360214 us-gaap:RetainedEarningsMember 2019-09-30 0001360214 us-gaap:ParentMember 2019-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-09-30 0001360214 2019-09-30 0001360214 us-gaap:CommonStockMember 2020-06-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001360214 us-gaap:RetainedEarningsMember 2020-06-30 0001360214 us-gaap:ParentMember 2020-06-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-06-30 0001360214 2020-06-30 0001360214 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001360214 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001360214 us-gaap:ParentMember 2020-07-01 2020-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001360214 us-gaap:CommonStockMember 2020-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001360214 us-gaap:RetainedEarningsMember 2020-09-30 0001360214 us-gaap:ParentMember 2020-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-09-30 0001360214 us-gaap:CommonStockMember 2018-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001360214 us-gaap:RetainedEarningsMember 2018-12-31 0001360214 us-gaap:ParentMember 2018-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2018-12-31 0001360214 2018-12-31 0001360214 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001360214 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001360214 us-gaap:ParentMember 2019-01-01 2019-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0001360214 us-gaap:CommonStockMember 2019-12-31 0001360214 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001360214 us-gaap:RetainedEarningsMember 2019-12-31 0001360214 us-gaap:ParentMember 2019-12-31 0001360214 us-gaap:NoncontrollingInterestMember 2019-12-31 0001360214 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001360214 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001360214 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001360214 us-gaap:ParentMember 2020-01-01 2020-09-30 0001360214 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember 2020-09-30 0001360214 HROW:StowePharmaceuticalsIncMember 2020-09-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember HROW:TGVHealthLLCMember 2020-09-30 0001360214 HROW:StowePharmaceuticalsIncMember HROW:TGVHealthLLCMember 2020-09-30 0001360214 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001360214 HROW:StockOptionsMember 2020-07-01 2020-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-07-01 2020-09-30 0001360214 HROW:EtonPharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 us-gaap:SeriesAPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2019-01-01 2019-03-31 0001360214 us-gaap:SeriesAPreferredStockMember HROW:MeltPharmaceuticalsIncMember 2019-03-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-01-01 2019-01-31 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-07-01 2020-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-07-01 2019-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-01-01 2019-09-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-09-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-07-01 2020-09-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2019-07-01 2019-09-30 0001360214 HROW:SurfacePharmaceuticalsIncMember 2019-01-01 2019-09-30 0001360214 HROW:CommissionsMember 2020-07-01 2020-09-30 0001360214 HROW:CommissionsMember 2019-07-01 2019-09-30 0001360214 HROW:CommissionsMember 2020-01-01 2020-09-30 0001360214 HROW:CommissionsMember 2019-01-01 2019-09-30 0001360214 us-gaap:LicenseMember 2020-07-01 2020-09-30 0001360214 us-gaap:LicenseMember 2019-07-01 2019-09-30 0001360214 us-gaap:LicenseMember 2020-01-01 2020-09-30 0001360214 us-gaap:LicenseMember 2019-01-01 2019-09-30 0001360214 HROW:AssetPurchaseAgreementMember HROW:MeltPharmaceuticalsIncMember 2018-12-01 2018-12-31 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2019-02-01 2019-02-28 0001360214 HROW:ManagementServicesAgreementMember HROW:MeltPharmaceuticalsIncMember 2020-09-30 0001360214 srt:MinimumMember HROW:AssetPurchaseAndLicenseAgreementMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 srt:MaximumMember HROW:AssetPurchaseAndLicenseAgreementMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:DrLindstromMember HROW:SurfacePharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:MeltPharmaceuticalsIncMember 2019-12-31 0001360214 HROW:ParkRestructuringMember 2019-07-01 2019-09-30 0001360214 HROW:ParkRestructuringMember 2019-01-01 2019-09-30 0001360214 srt:MinimumMember us-gaap:PatentsMember 2020-01-01 2020-09-30 0001360214 srt:MaximumMember us-gaap:PatentsMember 2020-01-01 2020-09-30 0001360214 us-gaap:PatentsMember 2020-09-30 0001360214 HROW:LicensesMember 2020-01-01 2020-09-30 0001360214 HROW:LicensesMember 2020-09-30 0001360214 us-gaap:TrademarksMember 2020-01-01 2020-09-30 0001360214 us-gaap:TrademarksMember 2020-09-30 0001360214 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0001360214 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-09-30 0001360214 us-gaap:TradeNamesMember 2020-01-01 2020-09-30 0001360214 us-gaap:TradeNamesMember 2020-09-30 0001360214 srt:MinimumMember HROW:NonCompetitionClauseMember 2020-01-01 2020-09-30 0001360214 srt:MaximumMember HROW:NonCompetitionClauseMember 2020-01-01 2020-09-30 0001360214 HROW:NonCompetitionClauseMember 2020-09-30 0001360214 HROW:StatePharmacyLicensesMember 2020-01-01 2020-09-30 0001360214 HROW:StatePharmacyLicensesMember 2020-09-30 0001360214 us-gaap:PatentsMember 2020-07-01 2020-09-30 0001360214 us-gaap:PatentsMember 2019-07-01 2019-09-30 0001360214 us-gaap:PatentsMember 2020-01-01 2020-09-30 0001360214 us-gaap:PatentsMember 2019-01-01 2019-09-30 0001360214 HROW:LicensesMember 2020-07-01 2020-09-30 0001360214 HROW:LicensesMember 2019-07-01 2019-09-30 0001360214 HROW:LicensesMember 2019-01-01 2019-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-07-01 2020-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0001360214 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-09-30 0001360214 us-gaap:TradeNamesMember 2020-07-01 2020-09-30 0001360214 us-gaap:TradeNamesMember 2019-07-01 2019-09-30 0001360214 us-gaap:TradeNamesMember 2019-01-01 2019-09-30 0001360214 HROW:StatePharmacyLicensesMember 2020-07-01 2020-09-30 0001360214 HROW:StatePharmacyLicensesMember 2019-07-01 2019-09-30 0001360214 HROW:StatePharmacyLicensesMember 2019-01-01 2019-09-30 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember HROW:SWKFundingLLCMember 2017-07-30 2017-07-31 0001360214 srt:MinimumMember HROW:TermLoanAndSecurityAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:TermLoanAndSecurityAgreementMember us-gaap:BaseRateMember HROW:SWKFundingLLCMember 2017-07-31 0001360214 HROW:SWKAmendmentMember 2020-04-02 0001360214 HROW:BusinessLoanAgreementMember 2020-04-30 0001360214 HROW:BusinessLoanAgreementMember 2020-04-03 2020-04-30 0001360214 HROW:NotesPayableMember 2020-07-01 2020-09-30 0001360214 HROW:NotesPayableMember 2020-01-01 2020-09-30 0001360214 HROW:NotesPayableMember 2019-07-01 2019-09-30 0001360214 HROW:NotesPayableMember 2019-01-01 2019-09-30 0001360214 HROW:SanDiegoMember 2020-09-30 0001360214 HROW:SanDiegoMember 2020-01-01 2020-09-30 0001360214 HROW:LedgewoodMember 2020-09-30 0001360214 HROW:LedgewoodMember 2020-01-01 2020-09-30 0001360214 HROW:LedgewoodMember HROW:AdditionalSquareFootageOfLeaseMember 2020-09-30 0001360214 HROW:NashvilleMember 2020-09-30 0001360214 HROW:NashvilleMember 2020-01-01 2020-09-30 0001360214 HROW:IrvineMember 2020-09-30 0001360214 HROW:IrvineMember 2020-07-01 2020-09-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-05-01 2020-05-31 0001360214 HROW:CommonStockOneMember 2020-01-01 2020-09-30 0001360214 srt:MinimumMember HROW:CommonStockOneMember 2020-01-01 2020-09-30 0001360214 srt:MaximumMember HROW:CommonStockOneMember 2020-01-01 2020-09-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001360214 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001360214 HROW:TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember 2020-09-30 0001360214 HROW:StockOptionPlanOneMember 2019-12-31 0001360214 HROW:StockOptionPlanOneMember 2020-01-01 2020-09-30 0001360214 HROW:StockOptionPlanOneMember 2020-09-30 0001360214 HROW:StockOptionPlanMember 2020-09-30 0001360214 HROW:EmployeesAndConsultantMember HROW:StockOptionPlanMember 2020-01-01 2020-09-30 0001360214 HROW:BaumPerformanceOptionMember 2015-07-30 2015-07-31 0001360214 srt:MinimumMember HROW:BaumPerformanceOptionMember 2015-07-31 0001360214 srt:MaximumMember HROW:BaumPerformanceOptionMember 2015-07-31 0001360214 HROW:BaumPerformanceOptionMember 2020-06-03 2020-06-04 0001360214 HROW:StockOptionPlanMember 2020-01-01 2020-09-30 0001360214 HROW:OptionsEmployeesMember 2020-01-01 2020-09-30 0001360214 srt:MinimumMember HROW:OptionsEmployeesMember 2020-01-01 2020-09-30 0001360214 srt:MaximumMember HROW:OptionsEmployeesMember 2020-01-01 2020-09-30 0001360214 HROW:RangeOneMember 2020-01-01 2020-09-30 0001360214 HROW:RangeOneMember 2020-09-30 0001360214 HROW:RangeTwoMember 2020-01-01 2020-09-30 0001360214 HROW:RangeTwoMember 2020-09-30 0001360214 HROW:RangeThreeMember 2020-01-01 2020-09-30 0001360214 HROW:RangeThreeMember 2020-09-30 0001360214 HROW:RangeFourMember 2020-01-01 2020-09-30 0001360214 HROW:RangeFourMember 2020-09-30 0001360214 HROW:StockOptionPlanMember 2020-07-01 2020-09-30 0001360214 HROW:BoardOfDirectorsMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001360214 HROW:NewMemberOfBoardOfDirectorsMember HROW:RestrictedStockUnitsRSUOneMember 2020-01-01 2020-09-30 0001360214 HROW:NewMemberOfBoardOfDirectorsOneMember HROW:RestrictedStockUnitsRSUOneMember 2020-07-01 2020-09-30 0001360214 HROW:NewMemberOfBoardOfDirectorsOneMember HROW:RestrictedStockUnitsRSUOneMember 2020-01-01 2020-09-30 0001360214 HROW:RestrictedStockUnitsRSUOneMember 2020-01-01 2020-09-30 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001360214 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001360214 HROW:UnvestedRSUMember 2020-09-30 0001360214 HROW:UnvestedRSUMember 2020-01-01 2020-09-30 0001360214 HROW:UnvestedRSUMember 2020-07-01 2020-09-30 0001360214 us-gaap:WarrantMember 2019-12-31 0001360214 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001360214 us-gaap:WarrantMember 2020-09-30 0001360214 HROW:LenderWarrantsMember 2020-01-01 2020-09-30 0001360214 HROW:LenderWarrantsMember 2020-09-30 0001360214 HROW:SettlementWarrantsMember 2020-01-01 2020-09-30 0001360214 HROW:SettlementWarrantsMember 2020-09-30 0001360214 HROW:LenderWarrantsOneMember 2020-01-01 2020-09-30 0001360214 HROW:LenderWarrantsOneMember 2020-09-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember HROW:EllePharmaceuticalLLCMember 2020-01-01 2020-09-30 0001360214 us-gaap:RestrictedStockMember HROW:MayfieldPharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:MayfieldPharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:ConsultantMember us-gaap:RestrictedStockMember HROW:MayfieldPharmaceuticalsIncMember 2020-01-01 2020-09-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-07-01 2020-09-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2019-07-01 2019-09-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-09-30 0001360214 HROW:EmployeesMember HROW:SellingGeneralAndAdministrativeMember 2019-01-01 2019-09-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-07-01 2020-09-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2019-07-01 2019-09-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-09-30 0001360214 srt:DirectorMember HROW:SellingGeneralAndAdministrativeMember 2019-01-01 2019-09-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2020-07-01 2020-09-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2019-07-01 2019-09-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2020-01-01 2020-09-30 0001360214 HROW:ConsultantMember HROW:SellingGeneralAndAdministrativeMember 2019-01-01 2019-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:SecondPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:FinalPaymentMember HROW:RichardLLindstromMDMember HROW:LicenseAgreementMember 2017-04-01 2017-04-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-07-01 2020-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:KlarityLicenseAgreementMember 2020-01-01 2020-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:InitialPaymentMember HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2019-12-01 2019-12-31 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-07-01 2020-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:InjectableAssetPurchaseAgreementMember 2020-01-01 2020-09-30 0001360214 HROW:RichardLLindstromMDMember 2020-01-01 2020-09-30 0001360214 HROW:DexycuAgreementMember 2020-08-01 2020-08-02 0001360214 HROW:DexycuAgreementMember 2020-07-01 2020-09-30 0001360214 HROW:DexycuAgreementMember 2020-01-01 2020-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:SalesAndMarketingAgreementsMember 2020-01-01 2020-09-30 0001360214 HROW:RichardLLindstromMDMember HROW:SalesAndMarketingAgreementsMember 2020-07-01 2020-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-07-01 2020-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2020-01-01 2020-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-07-01 2019-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-01-01 2019-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-09-30 0001360214 HROW:AssetPurchaseLicenseAndRelatedAgreementsMember 2019-12-31 0001360214 2020-01-01 2020-06-02 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2020-07-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-07-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0001360214 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2020-01-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2020-01-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0001360214 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2019-07-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2019-07-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0001360214 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalCompoundingMember 2019-01-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember HROW:PharmaceuticalDrugDevelopmentMember 2019-01-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0001360214 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0001360214 us-gaap:OperatingSegmentsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001360214 HROW:ThreeMainSuppliersMember 2020-07-01 2020-09-30 0001360214 HROW:ThreeMainSuppliersMember 2020-01-01 2020-09-30 0001360214 HROW:ThreeMainSuppliersMember 2019-07-01 2019-09-30 0001360214 HROW:ThreeMainSuppliersMember 2019-01-01 2019-09-30 0001360214 us-gaap:SubsequentEventMember 2020-10-01 2020-10-31 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001360214 false Q3 2020 --12-31 true Accelerated Filer

10-Q true 2020-09-30 false 001-35814 Harrow Health, Inc. DE 45-0567010 102 Woodmont Blvd. Suite 610 Nashville TN 37205 (615) 733-4730 Yes Yes false false Common Stock, $0.001 par value per share HROW NASDAQ 25745967

200000

5727000

4949000

27650000

25200000

2195000

2009000

3974000

3301000

1431000

1308000

40977000

36767000

4773000

5375000

6945000

6559000

1958000

2337000

2053000

3747000

2432000

3968000

332000

59470000

59085000

5691000

7702000

3692000

2117000

63000

57000

1138000

2612000

1772000

579000

629000

7000

13782000

12284000

6780000

6338000

20000

26000

800000

829000

12331000

12219000

34542000

31667000

0.001

50000000

25652169

25526931

26000

103798000

101728000

-78549000

-74043000

25275000

27711000

-347000

-293000

24928000

27418000

59470000

59085000

14385000

12748000

34244000

38540000

14000

7000

32000

21000

14399000

12755000

34276000

38561000

3696000

4061000

10526000

13184000

10703000

8694000

23750000

25377000

8436000

8608000

23806000

25399000

670000

444000

1822000

1659000

4040000

363000

4040000

9106000

13092000

25991000

31098000

1597000

-4398000

-2241000

-5721000

-498000

-620000

-1563000

-1939000

-300000

-682000

-1536000

4517000

-756000

-400000

-1694000

-904000

8575000

-5530000

2450000

700000

5000

24000

630000

7026000

-7232000

-2319000

3004000

8623000

-11630000

-4560000

-2717000

8623000

-11630000

-4560000

-2717000

-15000

-161000

-54000

-228000

8638000

-11469000

-4506000

-2489000

0.33

-0.45

-0.17

-0.10

0.32

-0.45

-0.17

-0.10

25921573

25583998

25880554

25205215

27090060

25583998

25880554

25205215

25138958

25000

100271000

-65231000

35065000

-67000

34998000

25135

4748

44000

75000

328000

-11469000

-161000

-11630000

25168841

25000

100630000

-76700000

23955000

-228000

23727000

25649171

26000

102889000

-87187000

15728000

-332000

15396000

2998

8000

917000

8638000

-15000

8623000

25652169

26000

103798000

-78549000

25275000

-347000

24928000

24339610

24000

98938000

-74211000

24751000

788528 1000 178000 179000 179000

25703

44000

15000

150000

1408000

-2489000

-228000

-2717000

25168841

25000

100630000

-76700000

23955000

-228000

23727000

25526931

26000

101728000

-74043000

27711000

-293000

27418000

3251

8000

91987

30000

83000

1995000

-4506000

-54000

-4560000

25652169

26000

103798000

-78549000

25275000

-347000

24928000

-4560000

-2717000

1377000

1365000

127000 175000 550000 386000

354000

394000

221000

2450000 700000 -1694000 -904000 -1536000 4517000

-5000

348000

363000 4013000

83000

150000

1995000

1408000

407000

901000

673000

1413000

123000

528000

-2555000

1721000

1575000

-371000

6000

-71000

-534000

-702000

4000

111000

279000

780000

589000

-891000

-864000

6000

744000

1000000

750000

282000

1967000

-8000 135000

2203000

-1641000

778000

-3207000

4949000

6838000

5727000

3631000

5527000 3431000 200000 200000 5727000 3631000

11000

1222000

1546000

936000

NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Company and Background Harrow Health, Inc. (together with its subsidiaries, partially owned companies and royalty arrangements unless the context indicates or otherwise requires, the “Company” or “Harrow”) specializes in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns one of the nation’s leading ophthalmology-focused pharmaceutical businesses, ImprimisRx. In addition to wholly owning ImprimisRx, the Company also has equity positions in Eton Pharmaceuticals, Inc. (“Eton”), Surface Ophthalmics, Inc. (“Surface”), and Melt Pharmaceuticals, Inc. (“Melt”), all companies that began as subsidiaries of Harrow. More recently, the Company founded drug development subsidiaries Mayfield Pharmaceuticals, Inc. (“Mayfield”) and Stowe Pharmaceuticals, Inc. (“Stowe”), among others. In 2020, Harrow created Visionology, Inc., which intends to launch an online eye health platform business. Harrow also owns royalty rights in various drug candidates being developed by Surface, Melt and Mayfield. The Company intends to continue to create, and hold equity and royalty rights in, new businesses that commercialize drug candidates that are internally developed or otherwise acquired or licensed from third parties. Basis of Presentation The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, as well as Mayfield (<span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_c20200930__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember_zRzYdubpBUv4" title="Equity method investment, ownership percentage">79% majority controlled) and Stowe (<span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_c20200930__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember_zADnJLpTlGcc" title="Equity method investment, ownership percentage">70% majority controlled) each subsidiaries of Harrow as of September 30, 2020. The remaining <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_c20200930__srt--OwnershipAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zuBZ1XrSGW3g" title="Equity method investment, ownership percentage">21% of Mayfield is owned by Elle Pharmaceutical, LLC (“Elle”), TGV-Health, LLC and its affiliated entities (collectively “TGV”) or other consultants. Mayfield was organized to develop women’s health-focused drug candidates. The remaining <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_c20200930__srt--OwnershipAxis__custom--StowePharmaceuticalsIncMember__dei--LegalEntityAxis__custom--TGVHealthLLCMember_zYK2EjW1RNRe" title="Equity method investment, ownership percentage">30% of Stowe is owned by TGV. Stowe was organized to develop ophthalmic drug candidates. All inter-company accounts and transactions have been eliminated in consolidation. Harrow consolidates entities in which it has a controlling financial interest. We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheets at September 30, 2020 and December 31, 2019 and the condensed consolidated statements of operations, stockholders’ equity and cash flows for the periods ended September 30, 2020 and 2019 include our accounts and those of our wholly owned subsidiaries as well as Mayfield and Stowe. Risks, Uncertainties and Liquidity The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. On March 18, 2020, the Centers for Medicare & Medicaid Services (“CMS”) released guidance for U.S. healthcare providers to limit all elective medical procedures in order to conserve personal protective equipment and limit exposure to COVID-19 during the pendency of the pandemic. In addition to limiting elective medical procedures, many hospitals and other healthcare providers have strictly limited access to their facilities during the pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and healthcare delivery, led to social distancing recommendations, stay-at-home orders and other restrictive measures, and created significant volatility in financial markets. Many of the Company’s customers use its drugs in procedures impacted by the CMS guidance to limit elective procedures. In addition, the Company and our business partners need access to healthcare providers and facilities to conduct clinical trials and other activities required to achieve regulatory clearance of products under development. The Company believes reductions in elective procedures in response to CMS guidance have had, and may in the future have, an adverse impact, which may be material, to the Company’s financial condition, liquidity and results of operations. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on its customers, all of which are uncertain and cannot be predicted. As of the date of filing of this Quarterly Report, the extent to which the COVID-19 pandemic may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. For further information, refer to “Risk Factors” in Part II, Item 1A of this Quarterly Report and information in the Company’s other filings with the Securities and Exchange Commission. During certain periods, including those impacted by the COVID-19 pandemic, the Company has incurred operating losses and negative cash flows from operations. The Company incurred operating losses of $2,241 and $5,721 for the nine months ended September 30, 2020 and 2019, respectively, and had an accumulated deficit of $78,549 and $74,043 as of September 30, 2020 and December 31, 2019, respectively. In addition, the Company used cash in operating activities of $534 and $702 for the nine months ended September 30, 2020 and 2019, respectively. While there is no assurance, management of the Company believes existing cash resources and restricted cash of $5,727 at September 30, 2020 together with cash generated from revenues, will be sufficient to sustain the Company’s planned level of operations for at least the next twelve months. However, estimates of operating expenses, working capital requirements and the future impact of the COVID-19 pandemic on its business could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses. The Company may seek to increase liquidity and capital resources through a variety of means which may include, but are not limited to: the sale of assets, investments and/or businesses; obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through sales. There is no guarantee that the Company will be able to obtain capital when needed on terms management deems acceptable, or at all.

0.79

0.70

0.21

0.30

We consolidate subsidiaries in which we hold and/or control, directly or indirectly, more than 50% of the voting rights.

-2241000

-5721000

78549000 74043000

-534000

-702000

5727000

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following represents an update for the three and nine months ended September 30, 2020 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented as operating segments. The Company has identified two operating segments as reportable segments. See Note 15 for more information regarding the Company’s reportable segments. Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the condensed consolidated statements of operations. The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0.8pt; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 0.8pt; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 95%; padding-right: 0.8pt; text-align: justify">net income or loss;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">each component of other income or loss.</td></tr> </table> Basic and Diluted Net Income (Loss) per Common Share Basic net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”) and warrants, outstanding during the period. Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested RSUs and warrants were 5,447,716 and 5,263,131 at September 30, 2020 and 2019, respectively, and, except for the three months ended September 30, 2020, are excluded from the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at September 30, 2020 and 2019 was 281,507 and 314,588, respectively. The following table shows the computation of basic net income (loss) per share of common stock for the three and nine months ended September 30, 2020 and 2019: SCHEDULE OF BASIC EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200701__20200930_zDxhEvVhD7M4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20190701__20190930_zL7OJN789Ld" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20200101__20200930_zluf6CDwrOp8" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20190101__20190930_zBPgHPxdHXG6" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_ecustom--NetIncomeLoss1_pn3n3_zP5wbjlNWgcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss) attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,638</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(11,469</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,489</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zZf13YGJXPKl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,921,573</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,583,998</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,880,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,205,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_z54cSa773AG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> For the three months ended September 30, 2020, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended September 30, 2020, consisted of the following: SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three months Ended</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8BW3WjNrhs7" style="width: 30%; text-align: right" title="Dilutive common equivalent shares">504,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zWI9BmkbXry7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares">663,745</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930_zHXwct1gMssd" style="border-bottom: Black 2.5pt double; text-align: right" title="Dilutive common equivalent shares">1,168,487</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table shows the computation of diluted net income (loss) per share of common stock for the three and nine months ended September 30, 2020 and 2019: SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200701__20200930_zfVDyI7DOX58" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20190701__20190930_zcBkTpdqcm67" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20200101__20200930_zPvzVrXmLNHl" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20190101__20190930_zd7JXCoi181k" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_pn3n3_zBG7JNrmGoB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss) attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,638</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(11,469</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,489</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_z5nSnrxKz6b2" style="vertical-align: bottom; background-color: White"> <td>Denominator – weighted average number of shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,921,573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,583,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,880,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,205,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zok3OFxxXqBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,168,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zpefBv5G9Fp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,090,060</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,583,998</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,880,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,205,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pii_uUSDPShares_z1BtAd6YcgT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> Investment in Eton Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 shares of Eton common stock, which represents approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20200930__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zxbRMcRFMiql" title="Equity method investment, ownership percentage">16.7% of the equity and voting interests of Eton as of September 30, 2020. At September 30, 2020 the fair market value of Eton’s common stock was $7.90 per share. In accordance with Accounting Standard’s Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, for the three and nine months ended September 30, 2020, the Company recorded an investment gain (loss) from its Eton common stock position of $8,575 and $2,450, respectively, related to the change in fair market value of the Company’s investment in Eton during the measurement periods. As of September 30, 2020, the fair market value of the Company’s investment in Eton was $27,650. Mark Baum, the Company’s Chief Executive Officer, is a member of the board of directors of Eton. Investment in Melt Pharmaceuticals, Inc. – Related Party In April 2018, the Company formed Melt as a wholly owned subsidiary. In January and March of 2019, Melt entered into definitive stock purchase agreements (collectively, the “Melt Series A Preferred Stock Agreement”) with certain investors and closed on the sale of Melt’s Series A Preferred Stock (the “Melt Series A Stock”), totaling approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn3n3_c20190101__20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHXhjn46ccSa" title="Proceeds from issuance of preferred stock and preference stock">11,400 of proceeds (collectively, the “Melt Series A Round”) at a purchase price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVOSA6rOujo9" title="Shares issued, price per share">5.00 per share. As a result, the Company lost voting and ownership control of Melt and ceased consolidating Melt’s financial statements. In January 2019, the Company deconsolidated Melt and recorded a gain of $5,810 and adjusted the carrying value in Melt to reflect the increased valuation of Melt and the Company’s new ownership interest in accordance with Accounting Standard Codification (“ASC”) 810-10-40-4(c), Consolidation. The Company owns 3,500,000 common shares of Melt (which is approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z1LaXeOgBKs" title="Equity method investment, ownership percentage">44% of the equity interests as of September 30, 2020) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Melt of $300 and $1,536 during the three and nine months ended September 30, 2020, respectively. The Company recorded equity in the net loss of Melt of $682 and $1,293 during the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the carrying value of the Company’s investment in Melt was $2,432. See Note 4 for more information and related party disclosure regarding Melt. Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zvUrpIz7H134" title="Equity method investment, ownership percentage">30% of the equity interests as of September 30, 2020) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Surface of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20200701__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zaHIwmgaUrdk" title="Unrealized gain (loss) on investments">756 and $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zWdmedy6HW34" title="Unrealized gain (loss) on investments">1,694 during the three and nine months ended September 30, 2020, respectively. The Company recorded equity in the net loss of Surface of $<span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20190701__20190930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zXxtYg6pgeAd" title="Unrealized gain (loss) on investments">400 and $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20190101__20190930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zdiOoZKACjSb" title="Unrealized gain (loss) on investments">904 during the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the carrying value of the Company’s investment in Surface was $2,053. See Note 5 for more information and related party disclosure regarding Surface. Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued ASU 2018-13, Changes to Disclosure Requirements for Fair Value Measurements, which improved the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted. The Company is currently assessing the impact of this standard and does not expect ASU 2019-12 to have a material impact on its consolidated financial position, results of operations and cash flows.

Segments The Company’s chief operating decision-maker is its Chief Executive Officer who makes resource allocation decisions and assesses performance based on financial information presented as operating segments. The Company has identified two operating segments as reportable segments. See Note 15 for more information regarding the Company’s reportable segments.

Noncontrolling Interests The Company recognizes any noncontrolling interest as a separate line item in equity in the condensed consolidated financial statements. A noncontrolling interest represents the portion of equity ownership in a less-than-wholly owned subsidiary not attributable to the Company. Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well. The Company includes the amount of net income (loss) attributable to noncontrolling interests in consolidated net income (loss) on the face of the condensed consolidated statements of operations. The Company provides in the condensed consolidated statements of stockholders’ equity a reconciliation at the beginning and the end of the period of the carrying amount of total equity, equity attributable to the parent, and equity attributable to the noncontrolling interests that separately discloses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0.8pt; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 0.8pt; text-align: justify">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 95%; padding-right: 0.8pt; text-align: justify">net income or loss;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">transactions with owners acting in their capacity as owners, showing separately contributions from and distributions to owners; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">(3)</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">each component of other income or loss.</td></tr> </table>

Generally, any interest that holds less than 50% of the outstanding voting shares is deemed to be a noncontrolling interest; however, there are other factors, such as decision-making rights, that are considered as well.

Basic and Diluted Net Income (Loss) per Common Share Basic net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options, restricted stock units (“RSUs”) and warrants, outstanding during the period. Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from stock options, unvested RSUs and warrants were 5,447,716 and 5,263,131 at September 30, 2020 and 2019, respectively, and, except for the three months ended September 30, 2020, are excluded from the calculation of diluted net income (loss) per share for the periods presented, because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at September 30, 2020 and 2019 was 281,507 and 314,588, respectively. The following table shows the computation of basic net income (loss) per share of common stock for the three and nine months ended September 30, 2020 and 2019: SCHEDULE OF BASIC EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200701__20200930_zDxhEvVhD7M4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20190701__20190930_zL7OJN789Ld" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20200101__20200930_zluf6CDwrOp8" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20190101__20190930_zBPgHPxdHXG6" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_ecustom--NetIncomeLoss1_pn3n3_zP5wbjlNWgcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss) attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,638</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(11,469</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,489</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zZf13YGJXPKl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,921,573</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,583,998</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,880,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,205,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_z54cSa773AG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> For the three months ended September 30, 2020, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended September 30, 2020, consisted of the following: SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three months Ended</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8BW3WjNrhs7" style="width: 30%; text-align: right" title="Dilutive common equivalent shares">504,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zWI9BmkbXry7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares">663,745</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930_zHXwct1gMssd" style="border-bottom: Black 2.5pt double; text-align: right" title="Dilutive common equivalent shares">1,168,487</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The following table shows the computation of diluted net income (loss) per share of common stock for the three and nine months ended September 30, 2020 and 2019: SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200701__20200930_zfVDyI7DOX58" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20190701__20190930_zcBkTpdqcm67" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20200101__20200930_zPvzVrXmLNHl" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20190101__20190930_zd7JXCoi181k" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_pn3n3_zBG7JNrmGoB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss) attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,638</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(11,469</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,489</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_z5nSnrxKz6b2" style="vertical-align: bottom; background-color: White"> <td>Denominator – weighted average number of shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,921,573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,583,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,880,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,205,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zok3OFxxXqBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,168,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zpefBv5G9Fp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,090,060</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,583,998</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,880,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,205,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pii_uUSDPShares_z1BtAd6YcgT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

5447716 5263131 281507 314588

The following table shows the computation of basic net income (loss) per share of common stock for the three and nine months ended September 30, 2020 and 2019: SCHEDULE OF BASIC EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20200701__20200930_zDxhEvVhD7M4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20190701__20190930_zL7OJN789Ld" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20200101__20200930_zluf6CDwrOp8" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20190101__20190930_zBPgHPxdHXG6" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_ecustom--NetIncomeLoss1_pn3n3_zP5wbjlNWgcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss) attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,638</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(11,469</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,489</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_zZf13YGJXPKl" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Denominator – weighted average number of shares outstanding, basic</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,921,573</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,583,998</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,880,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,205,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_pii_uUSDPShares_z54cSa773AG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, basic</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

8638000 -11469000 -4506000 -2489000

25921573

25583998

25880554

25205215

0.33

-0.45

-0.17

-0.10

For the three months ended September 30, 2020, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during the period. Diluted common equivalent shares for the three months ended September 30, 2020, consisted of the following: SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three months Ended</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Diluted shares related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 66%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z8BW3WjNrhs7" style="width: 30%; text-align: right" title="Dilutive common equivalent shares">504,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zWI9BmkbXry7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Dilutive common equivalent shares">663,745</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Dilutive common equivalent shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pii_c20200701__20200930_zHXwct1gMssd" style="border-bottom: Black 2.5pt double; text-align: right" title="Dilutive common equivalent shares">1,168,487</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

504742

663745

1168487

The following table shows the computation of diluted net income (loss) per share of common stock for the three and nine months ended September 30, 2020 and 2019: SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200701__20200930_zfVDyI7DOX58" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20190701__20190930_zcBkTpdqcm67" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20200101__20200930_zPvzVrXmLNHl" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20190101__20190930_zd7JXCoi181k" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_pn3n3_zBG7JNrmGoB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left; padding-bottom: 2.5pt">Numerator – net income (loss) attributable to Harrow Health, Inc.</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">8,638</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(11,469</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(4,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 12%; text-align: right">(2,489</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pii_z5nSnrxKz6b2" style="vertical-align: bottom; background-color: White"> <td>Denominator – weighted average number of shares outstanding, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,921,573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,583,998</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,880,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,205,215</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--IncrementalCommonSharesAttributableDilutiveCommonEquivalents_pii_zok3OFxxXqBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive common equivalent shares</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,168,487</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncrementalCommonSharesAttributableToContingentlyIssuableShares_pii_zpefBv5G9Fp1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Number of shares used for diluted earnings per share computation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,090,060</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,583,998</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,880,554</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,205,215</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareDiluted_pii_uUSDPShares_z1BtAd6YcgT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share, diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.32</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.45</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.17</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.10</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

8638000

-11469000

-4506000

-2489000

25921573

25583998

25880554

25205215

1168487

27090060

25583998

25880554

25205215

0.32

-0.45

-0.17

-0.10

Investment in Eton Pharmaceuticals, Inc. – Related Party The Company owns 3,500,000 shares of Eton common stock, which represents approximately <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20200930__dei--LegalEntityAxis__custom--EtonPharmaceuticalsIncMember_zxbRMcRFMiql" title="Equity method investment, ownership percentage">16.7% of the equity and voting interests of Eton as of September 30, 2020. At September 30, 2020 the fair market value of Eton’s common stock was $7.90 per share. In accordance with Accounting Standard’s Update (“ASU”) 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, for the three and nine months ended September 30, 2020, the Company recorded an investment gain (loss) from its Eton common stock position of $8,575 and $2,450, respectively, related to the change in fair market value of the Company’s investment in Eton during the measurement periods. As of September 30, 2020, the fair market value of the Company’s investment in Eton was $27,650. Mark Baum, the Company’s Chief Executive Officer, is a member of the board of directors of Eton.

3500000

0.167

7.90

8575000

2450000

27650000

Investment in Melt Pharmaceuticals, Inc. – Related Party In April 2018, the Company formed Melt as a wholly owned subsidiary. In January and March of 2019, Melt entered into definitive stock purchase agreements (collectively, the “Melt Series A Preferred Stock Agreement”) with certain investors and closed on the sale of Melt’s Series A Preferred Stock (the “Melt Series A Stock”), totaling approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn3n3_c20190101__20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHXhjn46ccSa" title="Proceeds from issuance of preferred stock and preference stock">11,400 of proceeds (collectively, the “Melt Series A Round”) at a purchase price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pii_c20190331__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zVOSA6rOujo9" title="Shares issued, price per share">5.00 per share. As a result, the Company lost voting and ownership control of Melt and ceased consolidating Melt’s financial statements. In January 2019, the Company deconsolidated Melt and recorded a gain of $5,810 and adjusted the carrying value in Melt to reflect the increased valuation of Melt and the Company’s new ownership interest in accordance with Accounting Standard Codification (“ASC”) 810-10-40-4(c), Consolidation. The Company owns 3,500,000 common shares of Melt (which is approximately <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_z1LaXeOgBKs" title="Equity method investment, ownership percentage">44% of the equity interests as of September 30, 2020) and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Melt. Under this method, the Company recognizes earnings and losses in Melt in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Melt accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Melt. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Melt of $300 and $1,536 during the three and nine months ended September 30, 2020, respectively. The Company recorded equity in the net loss of Melt of $682 and $1,293 during the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the carrying value of the Company’s investment in Melt was $2,432. See Note 4 for more information and related party disclosure regarding Melt.

11400000

5.00

5810000

3500000

0.44

300000

1536000

682000

1293000

2432000

Investment in Surface Ophthalmics, Inc. – Related Party The Company owns 3,500,000 common shares (which is approximately <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pii_dp_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zvUrpIz7H134" title="Equity method investment, ownership percentage">30% of the equity interests as of September 30, 2020) of Surface and uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Surface. Under this method, the Company recognizes earnings and losses in Surface in its condensed consolidated financial statements and adjusts the carrying amount of its investment in Surface accordingly. The Company’s share of earnings and losses are based on the Company’s ownership interest of Surface. Any intra-entity profits and losses are eliminated. The Company recorded equity in the net loss of Surface of $<span id="xdx_90F_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20200701__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zaHIwmgaUrdk" title="Unrealized gain (loss) on investments">756 and $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zWdmedy6HW34" title="Unrealized gain (loss) on investments">1,694 during the three and nine months ended September 30, 2020, respectively. The Company recorded equity in the net loss of Surface of $<span id="xdx_907_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20190701__20190930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zXxtYg6pgeAd" title="Unrealized gain (loss) on investments">400 and $<span id="xdx_902_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20190101__20190930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_zdiOoZKACjSb" title="Unrealized gain (loss) on investments">904 during the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the carrying value of the Company’s investment in Surface was $2,053. See Note 5 for more information and related party disclosure regarding Surface. 3500000

0.30

756000

1694000

400000

904000

2053000

Recently Adopted Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses. The Company adopted ASU 2016-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows. In August 2018, the FASB issued ASU 2018-13, Changes to Disclosure Requirements for Fair Value Measurements, which improved the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements. The Company adopted ASU 2018-13 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows. In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The Company adopted ASU 2017-04 on January 1, 2020, and adoption of the standard did not have a material effect on the Company’s consolidated financial position, results of operations and cash flows.

Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted. The Company is currently assessing the impact of this standard and does not expect ASU 2019-12 to have a material impact on its consolidated financial position, results of operations and cash flows.

NOTE 3. REVENUES The Company accounts for contracts with customers in accordance with ASC 606, Revenues from Contracts with Customers. The Company has two primary streams of revenues: (1) revenues recognized from our sale of products within our pharmacy services and (2) revenues recognized from intellectual property license and asset purchase agreements. Product Revenues from Pharmacy Services The Company sells prescription drugs directly through our pharmacy and outsourcing facility network. Revenues from our pharmacy services division includes: (i) the portion of the price the client pays directly to us, net of any volume-related or other discounts paid back to the client, (ii) the price paid to us by individuals, and (iii) customer copayments made directly to the pharmacy network. Sales taxes are not included in revenue. Following the core principle of ASC 606, we have identified the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the contract(s) with a customer: A contract exists with a customer at the time the prescription or order is received by the Company. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identify the performance obligations in the contract: The order received contains the performance obligations to be met, in almost all cases the product the customer is wishing to receive. If we are unable to be meet the performance obligation, the customer is notified. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determine the transaction price: the transaction price is based on the product being sold to the customer, and any related customer discounts. These amounts are pre-determined and built into our order management software. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocate the transaction price to the performance obligations in the contract: The transaction price associated with the product(s) being ordered is allocated according to the pre-determined amounts.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">5.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognize revenue when (or as) the entity satisfies a performance obligation: At the time of shipment from the pharmacy or outsourcing facility, the performance obligation has been met. </td></tr> </table> The following revenue recognition policy has been established for the pharmacy services division: Revenues generated from prescription or office use drugs sold by our pharmacies and outsourcing facility are recognized when the prescription is shipped. At the time of shipment, the pharmacy services division has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. The Company records reductions to revenue for discounts at the time of the initial sale. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded and are based on actual returns history. The rate of returns is analyzed annually to determine historical returns experience. If the historical data we use to calculate these estimates do not properly reflect future returns, then a change in the allowance would be made in the period in which such a determination is made and revenues in that period could be materially affected. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required. Commission Revenues During the third quarter of 2020, the Company entered into an agreement whereby it is paid a fee calculated based on sales it generates from a pharmaceutical product that is owned by a third party. The revenue earned from this arrangement is recognized at the time a customer has ordered the pharmaceutical product and it has shipped from the third party (or one of its distributors or affiliates), at which point there is no future performance obligation required by the Company and no consequential continuing involvement on the part of the Company to recognize the associated revenue. Intellectual Property License Revenues The Company currently holds five intellectual property license and related agreements in which the Company has sold or granted a license which provides a customer with the right to access the Company’s intellectual property. License arrangements may include or require non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple-element arrangements, the revenue of which is recognized at the point of time the performance obligation is met. Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term. Revenue disaggregated by revenue source for the three and nine months ended September 30, 2020 and 2019, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zBQ2kgnveBNh" style="width: 12%; text-align: right" title="Total Revenues">14,385</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z95a5dzcnfC8" style="width: 12%; text-align: right" title="Total Revenues">12,748</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zCvcrzjagus8" style="width: 12%; text-align: right" title="Total Revenues">34,244</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z5Fg0TrZ2MBh" style="width: 12%; text-align: right" title="Total Revenues">38,540</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930__srt--ProductOrServiceAxis__custom--CommissionsMember_zkRFSLfi2rog" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">License</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zAScP6fbj7w4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zPUp5V73433b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zlVSxDNzhGf8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z9zCmmFwrdwk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_zheXMtv5iW39" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">14,399</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_zvyQ47BU9E9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">12,755</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200930_zQtNqy8ODr6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">34,276</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930_zYUiR0kVkDO" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">38,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred revenue and customer deposits at September 30, 2020 and December 31, 2019, was $63 and $57, respectively. All deferred revenue and customer deposit amounts at December 31, 2019 were recognized as revenue during the nine months ended September 30, 2020.

Revenue disaggregated by revenue source for the three and nine months ended September 30, 2020 and 2019, consists of the following: SCHEDULE OF DISAGGREGATED REVENUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the Nine months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zBQ2kgnveBNh" style="width: 12%; text-align: right" title="Total Revenues">14,385</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z95a5dzcnfC8" style="width: 12%; text-align: right" title="Total Revenues">12,748</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_zCvcrzjagus8" style="width: 12%; text-align: right" title="Total Revenues">34,244</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930__srt--ProductOrServiceAxis__custom--ProductSalesNetMember_z5Fg0TrZ2MBh" style="width: 12%; text-align: right" title="Total Revenues">38,540</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Commissions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ProductOrServiceAxis__custom--CommissionsMember_pn3n3" style="text-align: right" title="Total Revenues">7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930__srt--ProductOrServiceAxis__custom--CommissionsMember_zkRFSLfi2rog" style="text-align: right" title="Total Revenues">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">License</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zAScP6fbj7w4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zPUp5V73433b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">7</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zlVSxDNzhGf8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">25</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseMember_z9zCmmFwrdwk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Revenues">21</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200701__20200930_zheXMtv5iW39" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">14,399</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190701__20190930_zvyQ47BU9E9h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">12,755</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20200101__20200930_zQtNqy8ODr6h" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">34,276</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_c20190101__20190930_zYUiR0kVkDO" style="border-bottom: Black 2.5pt double; text-align: right" title="Total Revenues">38,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

14385000

12748000

34244000

38540000

7000

25000

21000

14399000

12755000

34276000

38561000

63000

57000

<p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zrVgPiwRd4g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE 4. INVESTMENT IN MELT PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS In December 2018, the Company entered into an asset purchase agreement with Melt (the “Melt Asset Purchase Agreement”). Pursuant to the terms of the Melt Asset Purchase Agreement, Melt was assigned certain intellectual property and related rights from the Company to develop, formulate, make, sell, and sub-license certain Company conscious sedation and analgesia related formulations (collectively, the “Melt Products”). Under the terms of the Melt Asset Purchase Agreement, Melt is required to make royalty payments to the Company up to <span id="xdx_908_ecustom--RoyaltyPaymentPercentageOnNetSales_pii_c20181201__20181231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAgreementMember_zANdC8CyKTC3" title="Royalty payment percentage on net sales">5% of net sales of the Melt Products while any patent rights remain outstanding, as well as other conditions. In January and March 2019, the Company entered into the Melt Series A Preferred Stock Agreement. In February 2019, the Company and Melt entered into a Management Services Agreement (the “Melt MSA”), whereby the Company provides to Melt certain administrative services and support, including bookkeeping, web services and human resources related activities, and Melt pays the Company a monthly amount of $<span id="xdx_90F_eus-gaap--AdministrativeFeesExpense_pn3n3_c20190201__20190228__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zdv8fBH4gfl" title="Administrative expenses">10. As of September 30, 2020, the Company was due $<span id="xdx_908_eus-gaap--DueFromRelatedParties_iI_pn3n3_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--ManagementServicesAgreementMember_zFX2KQhkfew5" title="Reimbursable expenses due">815 from Melt for reimbursable expenses and amounts due under the Melt MSA and are included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets. During the three and nine months ended September 30, 2020, Melt did not make any payments to the Company. The Company’s Chief Executive Officer, Mark L. Baum, and Chief Medical Officer, Larry Dillaha, are members of the Melt board of directors. The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 71%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuAzWL62uDK8" style="border-bottom: Black 1.5pt solid; width: 25%; text-align: right" title="Loss from operations">3,261</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOaYZYvyC7Ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(3,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 81%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsCurrent_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 15%; text-align: right" title="Current assets">4,072</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">4,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Liabilities_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,452</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total preferred stock and stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockholdersEquity_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity">2,632</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesAndStockholdersEquity_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">4,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.05

10000

815000

The unaudited condensed results of operations information of Melt is summarized below: SCHEDULE OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 71%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--OperatingIncomeLoss_pn3n3_c20200101__20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zuAzWL62uDK8" style="border-bottom: Black 1.5pt solid; width: 25%; text-align: right" title="Loss from operations">3,261</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--NetIncomeLoss_pn3n3_c20200101__20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_zOaYZYvyC7Ef" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(3,261</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

3261000

-3261000

The unaudited condensed balance sheet information of Melt is summarized below: SCHEDULE OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 81%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsCurrent_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="width: 15%; text-align: right" title="Current assets">4,072</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsNoncurrent_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">4,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--Liabilities_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,452</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total preferred stock and stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--StockholdersEquity_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total preferred stock and stockholders' equity">2,632</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesAndStockholdersEquity_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">4,084</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4072000

12000

4084000

1452000

2632000

4084000

NOTE 5. INVESTMENT IN SURFACE OPHTHALMICS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS The Company entered into an asset purchase and license agreement with Surface in 2017, and amended it in April 2018 (the “Surface License Agreements”). Pursuant to the terms of the Surface License Agreements, the Company assigned and licensed to Surface certain intellectual property and related rights to develop, formulate, make, sell, and sub-license ophthalmic formulations (collectively, the “Surface Products”). Surface is required to make royalty payments to the Company of<span id="xdx_908_ecustom--RoyaltyPaymentPercentageOnNetSales_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAndLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_pii" title="Royalty payment percentage on net sales"> 4%-<span id="xdx_90A_ecustom--RoyaltyPaymentPercentageOnNetSales_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__us-gaap--TypeOfArrangementAxis__custom--AssetPurchaseAndLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_pii" title="Royalty payment percentage on net sales">6% of net sales of the Surface Products while any patent rights remain outstanding. A Company director, Richard L. Lindstrom, and the Company’s Chief Executive Officer, Mark L. Baum, are directors of Surface. Surface is required to make royalty payments to Dr. Lindstrom of <span id="xdx_906_ecustom--RoyaltyPaymentPercentageOnNetSales_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember__srt--TitleOfIndividualAxis__custom--DrLindstromMember_pii" title="Royalty payment percentage on net sales">3% of net sales of certain Surface Products while certain patent rights remain outstanding. Dr. Lindstrom is also a principal of Flying L Partners, an affiliate of the funding investor who purchased the Surface Series A Preferred Stock. The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 71%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 25%; text-align: right" title="Loss from operations">5,647</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(5,647</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsCurrent_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 20%; text-align: right" title="Current assets">11,547</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AssetsNoncurrent_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Assets_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">11,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Liabilities_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,754</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockholdersEquity_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">9,838</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesAndStockholdersEquity_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">11,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.04 0.06 0.03 The unaudited condensed results of operations information of Surface is summarized below: SUMMARY OF CONDENSED INCOME STATEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Nine Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenues, net</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Revenues, net">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 71%; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--OperatingIncomeLoss_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; width: 25%; text-align: right" title="Loss from operations">5,647</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_c20200101__20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(5,647</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

5647000

-5647000

The unaudited condensed balance sheet information of Surface is summarized below: SUMMARY OF CONDENSED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Current assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsCurrent_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="width: 20%; text-align: right" title="Current assets">11,547</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Non current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AssetsNoncurrent_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Non current assets">45</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Assets_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">11,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--Liabilities_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Total liabilities">1,754</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders’ equity</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--StockholdersEquity_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total stockholders equity">9,838</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders’ equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesAndStockholdersEquity_c20200930__dei--LegalEntityAxis__custom--SurfacePharmaceuticalsIncMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities and stockholders' equity">11,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

11547000

45000

11592000

1754000

9838000

11592000

NOTE 6. INVENTORIES Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of September 30, 2020 and December 31, 2019 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20200930_z35Vx0ryvdod" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20191231_zIhc6ls5aatc" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzl1A_zDd9s0XOOMJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,838</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,405</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzl1A_zHoC6IGjAX2f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzl1A_zSFpqoo21464" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,132</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">876</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzl1A_zse9gjGGYk78" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,301</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of September 30, 2020 and December 31, 2019 was as follows: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20200930_z35Vx0ryvdod" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20191231_zIhc6ls5aatc" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzl1A_zDd9s0XOOMJk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,838</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,405</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzl1A_zHoC6IGjAX2f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in progress</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzl1A_zSFpqoo21464" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,132</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">876</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iTI_pn3n3_mtINzl1A_zse9gjGGYk78" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,301</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2838000

2405000

4000

20000

1132000

876000

3974000

3301000

NOTE 7. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PrepaidInsurance_c20200930_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">149</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PrepaidInsurance_c20191231_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">123</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OtherPrepaidExpenseCurrent_c20200930_pn3n3" style="text-align: right" title="Other prepaid expenses">378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OtherPrepaidExpenseCurrent_c20191231_pn3n3" style="text-align: right" title="Other prepaid expenses">358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DueFromRelatedPartiesCurrent_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DueFromRelatedPartiesCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">722</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OtherAssetsCurrent_c20200930_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherAssetsCurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,431</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,308</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Prepaid expenses and other current assets consisted of the following: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--PrepaidInsurance_c20200930_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">149</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--PrepaidInsurance_c20191231_pn3n3" style="width: 16%; text-align: right" title="Prepaid insurance">123</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OtherPrepaidExpenseCurrent_c20200930_pn3n3" style="text-align: right" title="Other prepaid expenses">378</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--OtherPrepaidExpenseCurrent_c20191231_pn3n3" style="text-align: right" title="Other prepaid expenses">358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Receivable due from Melt</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DueFromRelatedPartiesCurrent_c20200930__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">815</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--DueFromRelatedPartiesCurrent_c20191231__dei--LegalEntityAxis__custom--MeltPharmaceuticalsIncMember_pn3n3" style="text-align: right" title="Receivable due from related party">722</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Deposits and other current assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OtherAssetsCurrent_c20200930_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--OtherAssetsCurrent_c20191231_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deposits and other current assets">105</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,431</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--PrepaidExpenseAndOtherAssetsCurrent1_c20191231_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total prepaid expenses and other current assets">1,308</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

149000

123000

378000

358000

815000

722000

89000

105000

1431000 1308000

NOTE 8. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment, net consisted of the following: SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_493_20200930_zwz60FFmp9Q5" style="text-align: center">2020</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20191231_zISkAxKm0Ucd" style="text-align: center">2019</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzOvw_zRW69g0QTmhd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Computer software and hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right" title="Computer software and hardware">1,902</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right" title="Computer software and hardware">1,732</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzOvw_zI4TbIda78yj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Furniture and equipment">463</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Furniture and equipment">363</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzOvw_z7Zs4MRsxZ4e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Lab and pharmacy equipment">3,464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Lab and pharmacy equipment">3,164</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzOvw_zBkLmjGE35Z5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Leasehold improvements">5,720</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Leasehold improvements">5,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzOvw_maPPAENz9zC_z4HqNfEFK7sh" style="vertical-align: bottom; background-color: White"> <td> Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Property, plant and equipment, gross">11,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Property, plant and equipment, gross">10,769</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9zC_zX5lWH85zMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation and amortization">(6,776</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation and amortization">(5,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9zC_zC1v6hqaUuRa" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plant and equipment, Net">4,773</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plant and equipment, Net">5,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the three and nine months ended September 30, 2020, depreciation and amortization related to the property, plant and equipment was $464 and $1,377, respectively. For the three and nine months ended September 30, 2019, depreciation related to the property, plant and equipment was $397 and $1,365, respectively. During the three and nine months ended September 30, 2019, the Company impaired $<span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pn3n3_c20190701__20190930__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--ParkRestructuringMember_zIpqTuWoSbi1" title="Impairment of property, plant and equipment"><span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn3n3_c20190101__20190930__us-gaap--LongLivedAssetsHeldForSaleByAssetTypeAxis__custom--ParkRestructuringMember_zJrFPBJY0bD5" title="Impairment of property, plant and equipment">445 of property, plant and equipment related to the Park Restructuring.

SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_493_20200930_zwz60FFmp9Q5" style="text-align: center">2020</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20191231_zISkAxKm0Ucd" style="text-align: center">2019</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property, plant and equipment, net:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CapitalizedComputerSoftwareGross_iI_pn3n3_maPPAEGzOvw_zRW69g0QTmhd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Computer software and hardware</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right" title="Computer software and hardware">1,902</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right" title="Computer software and hardware">1,732</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FurnitureAndFixturesGross_iI_pn3n3_maPPAEGzOvw_zI4TbIda78yj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Furniture and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Furniture and equipment">463</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Furniture and equipment">363</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--MachineryAndEquipmentGross_iI_pn3n3_maPPAEGzOvw_z7Zs4MRsxZ4e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Lab and pharmacy equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Lab and pharmacy equipment">3,464</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Lab and pharmacy equipment">3,164</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LeaseholdImprovementsGross_iI_pn3n3_maPPAEGzOvw_zBkLmjGE35Z5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Leasehold improvements">5,720</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Leasehold improvements">5,510</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3n3_mtPPAEGzOvw_maPPAENz9zC_z4HqNfEFK7sh" style="vertical-align: bottom; background-color: White"> <td> Property, plant and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Property, plant and equipment, gross">11,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Property, plant and equipment, gross">10,769</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENz9zC_zX5lWH85zMh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation and amortization">(6,776</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated depreciation and amortization">(5,394</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENz9zC_zC1v6hqaUuRa" style="vertical-align: bottom; background-color: White"> <td style="vertical-align: middle; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property, plant and equipment, net </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plant and equipment, Net">4,773</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Property, plant and equipment, Net">5,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1902000

1732000

463000

363000

3464000

3164000

5720000

5510000

11549000

10769000

6776000

5394000

4773000

5375000

464000

1377000

397000

1365000

445000

NOTE 9. INTANGIBLE ASSETS AND GOODWILL The Company’s intangible assets at September 30, 2020 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%">Patents</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zeq3XO19oyU2" title="Amortization periods (in years)">17-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zvc40oXo8Hhg" title="Amortization periods (in years)">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Cost">911</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Accumulated amortization">(86</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Impairment">(363</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Carrying value">462</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zfRK6XhVIU6c" title="Amortization periods (in years)">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center" title="Amortization periods description"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" title="Amortization periods description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost">353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value">353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zplt5ZxuMqmh" title="Amortization periods (in years)">3-<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zsejxoJR8Tkd" title="Amortization periods (in years)">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization">(421</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value">1,098</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z8QzZWs2JEs3" title="Amortization periods (in years)">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_z4XyKBYImyGk" title="Amortization periods (in years)">3-<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_ze7N3WYVzqzi" title="Amortization periods (in years)">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z3axqMD0DF78" title="Amortization periods (in years)">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,896</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(575</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(363</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">1,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the nine months ended September 30, 2020, the Company recorded impairment charges of $363 related to patent filings associated with products that the Company was no longer actively selling. Amortization expense for intangible assets for the three and nine months ended September 30, 2020 and 2019 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">Three Months Ended</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">Nine Months Ended</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlgZLHi3x26k" style="width: 12%; text-align: right" title="Amortization of intangible assets">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Amortization of intangible assets"><span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Amortization of intangible assets">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Estimated future amortization expense for the Company’s intangible assets at September 30, 2020 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20200930_ziESTFg6fHA5" style="text-align: right">2020</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zJfimddWeqrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">47</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zTFiqEQ4EAF5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zOkfvUSZb8Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zSUwYa3bdUFa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zM84i5Mu2J9a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zP0dlqM5Y6Rg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz6Td_z8UQtSCwUFn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> There have been no changes in the carrying value of the Company’s goodwill during the three and nine months ended September 30, 2020.

The Company’s intangible assets at September 30, 2020 consisted of the following: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">Amortization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: center">periods</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Accumulated</td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Net</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">(in years)</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Cost</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">amortization</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Impairment</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Carrying value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 15%">Patents</td><td style="width: 2%"> </td> <td style="width: 15%; text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MinimumMember_zeq3XO19oyU2" title="Amortization periods (in years)">17-<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__srt--RangeAxis__srt--MaximumMember_zvc40oXo8Hhg" title="Amortization periods (in years)">19 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Cost">911</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Accumulated amortization">(86</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Impairment">(363</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 13%; text-align: right" title="Net Carrying value">462</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: center"><span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zfRK6XhVIU6c" title="Amortization periods (in years)">20 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(6</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Net Carrying value">44</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Trademarks</td><td> </td> <td style="text-align: center" title="Amortization periods description"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationMethod_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember" title="Amortization periods description">Indefinite</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Cost">353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Accumulated amortization">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_pn3n3" style="text-align: right" title="Net Carrying value">353</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: center"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MinimumMember_zplt5ZxuMqmh" title="Amortization periods (in years)">3-<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember__srt--RangeAxis__srt--MaximumMember_zsejxoJR8Tkd" title="Amortization periods (in years)">15 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Cost">1,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Accumulated amortization">(421</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Net Carrying value">1,098</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_z8QzZWs2JEs3" title="Amortization periods (in years)">5 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Cost">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Accumulated amortization">(5</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition clause</td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MinimumMember_z4XyKBYImyGk" title="Amortization periods (in years)">3-<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember__srt--RangeAxis__srt--MaximumMember_ze7N3WYVzqzi" title="Amortization periods (in years)">4 years</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Cost">50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Accumulated amortization">(50</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompetitionClauseMember_pn3n3" style="text-align: right" title="Net Carrying value">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_z3axqMD0DF78" title="Amortization periods (in years)">25 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost">8</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accumulated amortization">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impairment">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net Carrying value">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost">2,896</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization">(575</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--FiniteLivedIntangibleAssetsImpairment_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Impairment">(363</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--IntangibleAssetsNetExcludingsGoodwill_c20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net Carrying value">1,958</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

P17Y

P19Y

911000

-86000

-363000 462000

P20Y

50000

-6000

44000

Indefinite

353000

P3Y

P15Y

1519000

-421000

1098000

P5Y

5000

-5000

P3Y

P4Y

50000

-50000

P25Y

8000

-7000

1000

2896000

-575000

-363000 1958000

363000

Amortization expense for intangible assets for the three and nine months ended September 30, 2020 and 2019 was as follows: SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">For the</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">Three Months Ended</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="6" style="text-align: center">Nine Months Ended</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zlgZLHi3x26k" style="width: 12%; text-align: right" title="Amortization of intangible assets">6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">22</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">25</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pn3n3" style="width: 12%; text-align: right" title="Amortization of intangible assets">37</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Licenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">33</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">128</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" style="text-align: right" title="Amortization of intangible assets">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Amortization of intangible assets"><span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_pn3n3" title="Amortization of intangible assets">1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">State pharmacy licenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right" title="Amortization of intangible assets"><span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--StatePharmacyLicensesMember_pn3n3" title="Amortization of intangible assets">4</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">127</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortization of intangible assets">175</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6000

22000

25000

37000

1000

5000

33000

26000

101000

128000

1000

3000

4000

39000

52000

127000

175000

Estimated future amortization expense for the Company’s intangible assets at September 30, 2020 is as follows: SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20200930_ziESTFg6fHA5" style="text-align: right">2020</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zJfimddWeqrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">47</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zTFiqEQ4EAF5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zOkfvUSZb8Se" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zSUwYa3bdUFa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zM84i5Mu2J9a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANz1kz_maFLIANz9py_maFLIANz6Td_zP0dlqM5Y6Rg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">893</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANz6Td_z8UQtSCwUFn9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

47000

173000

146000

893000

1605000

NOTE 10. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20200930_zNpE9n9ELXFg" style="text-align: center">2020</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20191231_z4X54JFhwtWa" style="text-align: center">2019</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zZD5B4P5UEal" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,511</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zsSPAIVpET1h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_z1XZSv9Uw3T5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zdgQDAsUno4h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for note payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzL96_zuDw51eSJXX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,491</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zFREyzfj6YFh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,691</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3_zHguRTGVAF72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Accounts payable and accrued expenses consisted of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_49A_20200930_zNpE9n9ELXFg" style="text-align: center">2020</td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20191231_z4X54JFhwtWa" style="text-align: center">2019</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">September 30,</td><td> </td><td> </td> <td colspan="2" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zZD5B4P5UEal" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,511</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,409</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherAccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zsSPAIVpET1h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_z1XZSv9Uw3T5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">244</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pn3n3_maAPAALzL96_zdgQDAsUno4h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Accrued exit fee for note payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iTI_pn3n3_mtAPAALzL96_zuDw51eSJXX3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total accounts payable and accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,491</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iNI_pn3n3_di_zFREyzfj6YFh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,691</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--AccountsPayableAndAccruedLiabilitiesNoncurrent_iI_pn3n3_zHguRTGVAF72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">800</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5511000

7409000

49000

180000

244000

800000

6491000

8502000

5691000

7702000

800000

NOTE 11. DEBT In July 2017, the Company entered into a term loan and security agreement in the principal amount of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember_ztTzfIUtjLpg" title="Debt principal amount">16,000 (the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (collectively, “SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five-year term; however, such term could be reduced to four years if certain revenue requirements are not achieved. The SWK Loan is secured by substantially all of the Company’s assets, including its intellectual property rights. The SWK Loan was subsequently amended in May 2019 and again in April 2020 (see below). <span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20170730__20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember" title="Debt instrument interest rate description">The SWK Loan bears an interest rate that is equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_uPercent_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--LondonInterbankOfferedRateLIBORMember__srt--RangeAxis__srt--MinimumMember_zVW3zjkZHgBg" title="Debt instrument interest rate">2.00%), plus an applicable margin of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_uPercent_c20170731__us-gaap--TypeOfArrangementAxis__custom--TermLoanAndSecurityAgreementMember__dei--LegalEntityAxis__custom--SWKFundingLLCMember__us-gaap--VariableRateAxis__us-gaap--BaseRateMember_z5fO5O5iCtU7" title="Debt instrument interest rate">10.00% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%. The leverage ratio means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding 12 month period, adding-back (i) actual litigation expenses for the immediately preceding 12 month period, minus (ii) actual litigation expenses for the immediately preceding 3 month period multiplied by 4. Second Amendment to SWK Loan On April 1, 2020, the Company and several of its wholly owned subsidiaries entered into a second amendment (the “SWK Amendment”) to the SWK Loan, with SWK. A summary of the material changes contained in the SWK Amendment are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 96%; text-align: justify">SWK agreed to make available to the Company, and the Company drew down on, an additional principal amount of $1,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The definition of the first amortization date was changed to August 14, 2020, permitting the Company to pay interest only on the principal amount loaned for the next payment (payments are due on a quarterly basis) following the SWK Amendment; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The interest payment due May 14, 2020 will be paid in kind by increasing the principal amount of the term loans by an amount equal to the interest accrued as of such date.</td></tr> </table> Paycheck Protection Program Loan In April 2020, the Company entered into an unsecured promissory note and related Business Loan Agreement with Renasant Bank, as lender, for a loan (the “PPP Loan”) in the principal amount of $1,967 and received cash proceeds of the same amount, pursuant to the Paycheck Protection Program (the “PPP”) under the Federal Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted March 27, 2020. The PPP is administered by the U.S. Small Business Administration. Under the terms of the PPP Loan, interest accrues on the outstanding principal at the rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pii_uPercent_c20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember_zBPfOo1KLpc" title="Debt instrument interest rate">1.0% per annum. The term of the PPP Loan is two years, unless sooner required in connection with an event of default under the PPP Loan. To the extent the PPP Loan amount is not forgiven under the PPP, the Company is obligated to make equal monthly payments of principal and interest, beginning seven months from the date of the PPP Loan, until the maturity date. The CARES Act and the PPP provide a mechanism for forgiveness of up to the full amount borrowed. Under the PPP, the Company may apply for and be granted forgiveness for all or part of the PPP Loan. The amount of loan proceeds eligible for forgiveness is based on a formula that takes into account a number of factors, including the amount of loan proceeds used by the Company during the eight-week period after the loan origination for certain purposes including payroll costs, interest on certain mortgage obligations, rent payments on certain leases, and certain qualified utility payments (<span id="xdx_907_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20200403__20200430__us-gaap--TypeOfArrangementAxis__custom--BusinessLoanAgreementMember" title="Debt instrument interest rate description">it being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs); the employer maintaining or rehiring employees and maintaining salaries at certain levels; and other factors. Subject to the other requirements and limitations on loan forgiveness, only loan proceeds spent on payroll and other eligible expenses during the covered eight-week period will qualify for forgiveness. While the Company has used proceeds from the PPP Loan for such qualifying expenses, in particular maintaining continuity of its payroll and workforce (including staff critical to the timely production and dispensing of medicines the Company produces), no assurance can be provided that the Company will apply for and subsequently obtain forgiveness of the PPP Loan in whole or in part. At September 30, 2020, future minimum payments under the Company’s debt agreements were as follows: SUMMARY OF FUTURE MINIMUM PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_49E_20200930_z4JTTmqtk4qd" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzze4_maLTDz6SQ_zdxfA8TNlBeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,299</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzze4_maLTDz6SQ_z9ZLIx8apZUe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,430</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzze4_maLTDz6SQ_zqiey2RMXme3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,437</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzze4_maLTDz6SQ_za5YF0qqE4N6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,669</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz6SQ_zua0cT1lMOK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,835</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zdRYCwARkMU6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less: amount representing estimated interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,020</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zdacGj7mhok5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loans payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,815</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zf1BJQovZuHd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less: unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(905</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NotesPayable_iI_pn3n3_zxULXz9sZI1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,910</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NotesPayableCurrent1_iI_pn3n3_zUAGNTywB5pc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less: current portion, net of unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--LongTermNotesPayable1_iI_pn3n3_zURxieegDBG3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Loans payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> For the three and nine months ended September 30, 2020, debt discount amortization related to the SWK loan payable was $111 and $354, respectively. For the three and nine months ended September 30, 2019, debt discount amortization related to the SWK loan payable was $127 and $377, respectively.

16000000

The SWK Loan bears an interest rate that is equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 2.00%), plus an applicable margin of 10.00% (the “Margin Rate”); provided that, if, two days prior to a payment date, the Company provides SWK evidence that the Company has achieved a leverage ratio as of such date of less than 4.00:1:00, the Margin Rate shall equal 9.00%; and if the Company has achieved a leverage ratio as of such date of less than 3.00:1:00, the Margin Rate shall equal 7.00%. The leverage ratio means, as of any date of determination, the ratio of: (a) indebtedness as of such date to (b) EBITDA (as defined in the SWK Loan), of the Company for the immediately preceding 12 month period, adding-back (i) actual litigation expenses for the immediately preceding 12 month period, minus (ii) actual litigation expenses for the immediately preceding 3 month period multiplied by 4.

0.0200

0.1000

1000000

1967000

0.010

it being anticipated that at least 75% of the loan amount will be required to be used for eligible payroll costs

At September 30, 2020, future minimum payments under the Company’s debt agreements were as follows: SUMMARY OF FUTURE MINIMUM PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" id="xdx_49E_20200930_z4JTTmqtk4qd" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzze4_maLTDz6SQ_zdxfA8TNlBeg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,299</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzze4_maLTDz6SQ_z9ZLIx8apZUe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,430</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzze4_maLTDz6SQ_zqiey2RMXme3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,437</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzze4_maLTDz6SQ_za5YF0qqE4N6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,669</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDz6SQ_zua0cT1lMOK6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,835</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iNI_pn3n3_di_zdRYCwARkMU6" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less: amount representing estimated interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,020</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DebtInstrumentCarryingAmount_iI_pn3n3_zdacGj7mhok5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Loans payable, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,815</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pn3n3_di_zf1BJQovZuHd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less: unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(905</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--NotesPayable_iI_pn3n3_zxULXz9sZI1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,910</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--NotesPayableCurrent1_iI_pn3n3_zUAGNTywB5pc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Less: current portion, net of unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,750</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_ecustom--LongTermNotesPayable1_iI_pn3n3_zURxieegDBG3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Loans payable, net of current portion and unamortized debt discount</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,160</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1299000

5430000

4437000

9669000

20835000

3020000

17815000

905000

16910000

-3750000 13160000

111000

354000

127000

377000

NOTE 12. LEASES The Company’s leases of office and laboratory space under the non-cancelable operating leases listed below. These lease agreements have remaining lease terms between one to four years and contain various clauses for renewal at our option. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 10,200 square feet of office space in San Diego, California that expires in December 2021, with an option to extend the term for a five-year period;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 26,400 square feet of lab, warehouse and office space in Ledgewood, New Jersey, that expires in July 2026, with an option to extend the term for two additional five-year periods. This includes an amendment that was made effective July 2020 that extended the term of the original lease and added <span id="xdx_907_eus-gaap--AreaOfLand_iI_pii_uSqft_c20200930__us-gaap--LeaseContractualTermAxis__custom--AdditionalSquareFootageOfLeaseMember__srt--StatementGeographicalAxis__custom--LedgewoodMember_zYZHcnBnbIdj">1,400 of additional square footage to the lease; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">An operating lease for 5,500 square feet of office space in Nashville, Tennessee, that expires in December 2024, with an option to extend the term for two additional five-year periods.</td></tr> </table> During the three months ended September 30, 2020, the Company terminated its operating lease for 4,500 square feet of office and lab space in Irvine, California that had an expiration date in December 2020. In connection with the termination, the Company recorded a gain of $4 which was recognized in other income (expense) on the condensed consolidated financial statements. At September 30, 2020, the weighted average incremental borrowing rate and the weighted average remaining lease term for the operating leases held by the Company were 6.33% and 11.38 years, respectively. During the three and nine months ended September 30, 2020, cash paid for amounts included for the operating lease liabilities was $258 and $805, respectively, and the Company recorded operating lease expense of $261 and $816, respectively, included in selling, general and administrative expenses. Future lease payments under operating leases as of September 30, 2020 were as follows: SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200930_z9ZijYzO88ph" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zrTl2AL9jgq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zQ217j3JtWD7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,017</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zWJQCse2rIk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,038</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zO26O61Xxrka" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zjageykB1kw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzvpd_z0ZPZNKevC8l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,056</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzvpd_maOLLzIHS_zqvqV5JDbQ74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,515</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzIHS_zzzwg1uwjHWc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zMcaRTGoYEF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,359</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zmq4BhizmwUl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--OperatingLeaseLiabilitiesNonCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,780</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company also has a finance lease that is included in its lease accounting but is not considered significant. Future lease payments under finance leases as of September 30, 2020 were as follows: SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200930_zSi6fFPUPK4j" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zaRtbCc0iwQh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_znTn3wyegrN8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zVzUf9lRdla8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zoay4ZZuRKeh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zqtZrWXlaoT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzij9_maFLLzZVG_zgSUQha7YgM6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maFLLzZVG_zJXtNisg29xj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zPjTIFNVlJyg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_zqVYeaAm6D0c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zfRMfdP7udz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> At September 30, 2020, the incremental borrowing rate and the remaining lease term for the finance lease held by the Company were 6.36% and 3.33 years, respectively. For the three and nine months ended September 30, 2020, depreciation expense related to the equipment held under the finance lease obligation was $<span id="xdx_90A_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_pn3n3_c20200701__20200930_zlkyP9Qv7oP8" title="Operating leases, income statement, depreciation expense on property subject to or held-for-lease">2 and $<span id="xdx_90F_eus-gaap--OperatingLeasesIncomeStatementDepreciationExpenseOnPropertySubjectToOrHeldForLease_pn3n3_c20200101__20200930_zfK2D2insOj2" title="Operating leases, income statement, depreciation expense on property subject to or held-for-lease">6, respectively. For the three and nine months ended September 30, 2020, cash paid and expense recognized for interest expense related to the finance lease obligation was $0 and $1, respectively.

10200

December 2021

term for a five-year period

26400

July 2026

term for two additional five-year periods

1400

5500

December 2024

term for two additional five-year periods

4500

December 2020

4000

0.0633

P11Y4M17D

258000 805000

261000

816000

Future lease payments under operating leases as of September 30, 2020 were as follows: SCHEDULE OF FUTURE LEASE PAYMENT UNDER OPERATING LEASES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200930_z9ZijYzO88ph" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Leases</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zrTl2AL9jgq9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zQ217j3JtWD7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,017</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zWJQCse2rIk5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,038</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zO26O61Xxrka" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,064</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maLOLLPzt4I_maLOLLPzvpd_zjageykB1kw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_maLOLLPzvpd_z0ZPZNKevC8l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,056</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3n3_mtLOLLPzvpd_maOLLzIHS_zqvqV5JDbQ74" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,515</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maOLLzIHS_zzzwg1uwjHWc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,156</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_zMcaRTGoYEF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total operating lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,359</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pn3n3_di_zmq4BhizmwUl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, operating lease liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40D_ecustom--OperatingLeaseLiabilitiesNonCurrent_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,780</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

250000

1017000

1038000

1064000

1090000

6056000

10515000

3156000

7359000

579000

6780000

Future lease payments under finance leases as of September 30, 2020 were as follows: SCHEDULE OF FUTURE LEASE PAYMENT UNDER FINANCE LEASE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200930_zSi6fFPUPK4j" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Finance Leases</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zaRtbCc0iwQh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 76%">Remainder of 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_znTn3wyegrN8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zVzUf9lRdla8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zoay4ZZuRKeh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_maFLLPDz8Hr_maFLLPDzij9_zqtZrWXlaoT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pn3n3_mtFLLPDzij9_maFLLzZVG_zgSUQha7YgM6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pn3n3_di_maFLLzZVG_zJXtNisg29xj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest payments</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FinanceLeaseLiability_iI_pn3n3_zPjTIFNVlJyg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">27</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinanceLeaseLiabilitiesCurrent_iI_pn3n3_zqVYeaAm6D0c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion, finance lease obligation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FinanceLeaseLiabilityNoncurrent_iI_pn3n3_zfRMfdP7udz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Finance lease obligation, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2000

9000

1000

30000

3000

27000

-7000

20000

0.0636

P3Y3M29D

2000

6000

1000

NOTE 13. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Common Stock In May 2020, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200501__20200531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares">30,000 shares of its restricted common stock, with a fair value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200501__20200531__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pn3n3" title="Fair value of restricted common stock issued">167, as consideration for commission expenses incurred during the year ended December 31, 2019 and the nine months ended September 30, 2020. During the nine months ended September 30, 2020, the Company issued 253 shares of its common stock upon the cashless exercise of 750 options to purchase common stock, with an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20200930_zyA7AGrM4Gzf" title="Exercise price of options">3.04 per share, net of 69 shares of common stock withheld for payroll tax withholdings. During the nine months ended September 30, 2020, the Company issued <span id="xdx_90A_ecustom--NumberOfCommonStockIssuedOnCashlessExercise_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_pii" title="Number of common stock issued on cashless exercise">2,998 shares of its common stock upon the exercise of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_pii" title="Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross">2,998 options to purchase common stock, with exercise prices ranging from $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember__srt--RangeAxis__srt--MinimumMember_zRdxT9lhRoGg" title="Exercise price of options">3.04 to $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember__srt--RangeAxis__srt--MaximumMember_ziUcEmYB1kX2" title="Exercise price of options">3.20 per share, and paid $<span id="xdx_907_ecustom--CommonStockWithheldForPayrollTaxWithholdingsValue_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_pn3n3" title="Common stock withheld for payroll tax withholdings, value">8 related to payroll tax withholdings. During the nine months ended September 30, 2020, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" title="Shares issued of restricted common stock, shares">91,987 shares of its common stock underlying RSUs held by a director that resigned. The RSUs had previously vested, including 2,429 RSUs during the nine months ended September 30, 2020, but the issuance and delivery of the shares were deferred until the director resigned. During the nine months ended September 30, 2020, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_pii" title="Shares issued of restricted common stock, shares">46,762 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the resignation of a director. Stock Option Plan On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). The 2007 Plan reached its term in September 2017, and we can no longer issue additional awards under this plan, however, options previously issued under the 2007 Plan will remain outstanding until they are exercised, reach their maturity or are otherwise cancelled/forfeited. On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan (the “2017 Plan” together with the 2007 Plan, the “Plans”). As of September 30, 2020, the 2017 Plan provides for the issuance of a maximum of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Maximum number of common stock issuance under the plan">2,000,000 shares of the Company’s common stock. The purpose of the Plans are to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors. The Company had <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20200930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenIncentiveStockandAwardsPlanMember_pii" title="Shares available for future issuances">342,882 shares available for future issuances under the 2017 Plan at September 30, 2020. Stock Options A summary of stock option activity under the Plans for the nine months ended September 30, 2020 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Options outstanding - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z5g56Mx1TR29" style="width: 12%; text-align: right" title="Number of shares, Outstanding, Beginning balance">2,656,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zgrtLChgDJGd" style="width: 12%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance">5.30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Number of shares, Options granted">414,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted">6.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zXVtheveefm8" style="text-align: right" title="Number of shares, Options exercised">(3,748</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised">3.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zml4SfZnasO5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited">(14,369</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited">17.42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options outstanding - September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zYVAIR18Qzw" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance">3,053,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zW8sJPTV1Qp5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance">5.41</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs9RmlJ68GGg" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zgQCuQ62DRn1" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding">3,608</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable – September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z72YgmfIaCN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable">1,855,150</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zHiEXOpdNiSk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance">4.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGiJAjJDsAga" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.38</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z33Cwt2oOSb2" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable">3,294</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Options vested and expected to vest – September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z677C03jDKni" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest">2,940,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zih8ASpNrTvj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest">5.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWablAkrYGze" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zXEgXA4KDIMd" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest">3,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on September 30, 2020, based on the closing price of the Company’s common stock of $5.59 on that date. During the nine months ended September 30, 2020, the Company granted stock options to certain employees and a consultant. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zI6JNcrbYakk" title="Weighted avg. remaining contractual life, options exercisable">10 years. <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember__srt--TitleOfIndividualAxis__custom--EmployeesAndConsultantMember_zC9ZPI9XMvie" title="Share-based compensation arrangement by share-based payment award, plan modification, description and terms">Vesting terms for options granted to employees and consultants during the nine months ended September 30, 2020 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement. On July 31, 2015, the Company granted to its Chief Executive Officer, Mark Baum, an option (the “Baum Performance Option”) to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_ztwXFm8QXcri" title="Number of shares, options granted">600,000 shares of the Company’s common stock at an exercise price of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20150730__20150731__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zxs07OLSmcfh" title="Exercise price of options">7.87 per share under the 2007 Plan subject to the satisfaction of certain market-based vesting criteria. The market-based vesting criteria are separated into five tranches and require that the Company achieve and maintain certain average stock price targets ranging from $9 per share to $15 per share during the five year period following the grant date. On June 4, 2020, the Company amended the Baum Performance Option, to extend the vesting and contractual term by <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zStSBvY9rSb2" title="Weighted avg. remaining contractual life, options outstanding">5 years. The Company treated this amendment as a modification to the Baum Performance Option for accounting purposes. The fair value of the modification was $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_z2G3QoUybFoa" title="Share-based compensation arrangement by share-based payment award, options, vested in period, fair value">1,876 using a Monte Carlo Simulation with a five year life, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_uPercent_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zJkkaLoiOzHe" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate">70% volatility and a risk-free interest rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_uPercent_c20200603__20200604__us-gaap--TypeOfArrangementAxis__custom--BaumPerformanceOptionMember_zLFTmppCz2ij" title="Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate">0.40%. With the exception of the Baum Performance Option, the fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture rate of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant. The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" title="Weighted-average fair value of options granted">3.86</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_ziN3DsiJ5wig" title="Expected terms (in years)">0.5 – <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zFnb9jTmQ5La" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z64v5AcTbyf7" title="Expected volatility, minimum">66.5% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zgDr1ApzWLh9" title="Expected volatility, maximum">71.4%</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zPRtiGANLAk3" title="Risk-free interest rate, minimum">0.34% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z5SbuESlI1oi" title="Risk-free interest rate, maximum">1.64%</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_d0_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zOfFiHwX4pg5" title="Dividend yield">-</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxKzIp82N8hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at September 30, 2020: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="4" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center">Weighted </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center">Average</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Weighted </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Weighted </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center">Remaining </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Average</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center">Number </td><td style="text-align: center"> </td> <td style="text-align: center">Contractual </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Exercise</td><td style="text-align: center"> </td> <td style="text-align: center">Number</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Exercise</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left">Range of Exercise Prices</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Life in Years</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zwYgk4vLbwCi" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum">2.60</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of Options Outstanding">778,690</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zzWuIDZG8am5" title="Weighted Average Remaining Contractual Life in Years">5.90</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBz5Uaz7DNZi" title="Weighted Average Exercise Price">2.05</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number Exercisable">728,938</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Weighted Average Exercisable Exercise Price">2.07</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, minimum">2.76 - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum">4.66</td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of Options Outstanding">531,785</td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgk6lG6U6uB8" title="Weighted Average Remaining Contractual Life in Years">5.95</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zq38Mb9apaQd" title="Weighted Average Exercise Price">3.98</td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number Exercisable">453,157</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Weighted Average Exercisable Exercise Price">3.98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum">5.49 - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum">6.36</td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Number of Options Outstanding">496,350</td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zHC4Ww9zVC3b" title="Weighted Average Remaining Contractual Life in Years">7.47</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcxAyl2J4Qmk" title="Weighted Average Exercise Price">6.10</td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Number Exercisable">263,814</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Weighted Average Exercisable Exercise Price">6.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, minimum">6.64 - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, maximum">8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Number of Options Outstanding">1,246,241</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCkNtCNvCqY4" title="Weighted Average Remaining Contractual Life in Years">5.42</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAQxHsyxuDp1" title="Weighted Average Exercise Price">7.85</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Number Exercisable">409,241</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Weighted Average Exercisable Exercise Price">8.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">$1.47 - $8.99</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,053,066</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930_zgyhtu30kdQd" title="Weighted Average Remaining Contractual Life in Years">5.97</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930_z2ClVLEek593" title="Weighted Average Exercise Price">5.41</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,855,150</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930_pii" title="Weighted Average Exercisable Exercise Price">4.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2020, there was approximately $6,021 of total unrecognized compensation expense related to unvested stock options granted under the Plans. That expense is expected to be recognized over the weighted-average remaining vesting period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanMember_zHw8Oxo78dC6">4.03 years. The stock-based compensation expense for all stock options was $559 and $1,094 during the three and nine months ended September 30, 2020, respectively. Restricted Stock Units RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. During the nine months ended September 30, 2020, the Company’s board of directors were granted <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zGVyIKc14ND4" title="Vesting of RSUs, shares">68,024 RSUs with a fair market value $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember_zmA3TBlvcYN1" title="Vesting of RSUs, value">400 which vest on a quarterly basis, over one year in equal installments. During the nine months ended September 30, 2020, the Company granted <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsMember_zvNi1bcoWqEa" title="Shares issued of restricted common stock, shares">10,000 RSUs to a new member of its board of directors, with a fair market value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsMember_pn3n3" title="Fair value of restricted common stock issued">39 which vest on the one-year anniversary of the grant date. During the three and nine months ended September 30, 2020, the Company granted <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200701__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsOneMember_zuI471Q70Q7i" title="Shares issued of restricted common stock, shares"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsOneMember_z2uaUkGA4MHi">12,500 RSUs to a new member of its board of directors, with a fair market value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200701__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsOneMember_pn3n3" title="Fair value of restricted common stock issued"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember__srt--TitleOfIndividualAxis__custom--NewMemberOfBoardOfDirectorsOneMember_zXt5vA2ne4Vj">72 which vest on the one-year anniversary of the grant date. During the nine months ended September 30, 2020, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember_pii" title="Shares issued of restricted common stock, shares">161,000 RSUs with a fair market value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20200930__us-gaap--AwardTypeAxis__custom--RestrictedStockUnitsRSUOneMember_pn3n3" title="Fair value of restricted common stock issued">1,025 were issued to certain employees; the RSUs vest in full on the third anniversary of the grant date. A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2020 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">RSUs unvested - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUoSybrnu65" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,411,930</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmZr2pttm21i" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">2.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted">251,524</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4IyVH2TMkbd" style="text-align: right" title="Number of RSUs vested">(49,190</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVfgw0ZcqO7h" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">6.61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFA46lSw1EV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgytN8YKcd9k" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">1,614,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za9muqVwTpa2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">3.16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of September 30, 2020, the total unrecognized compensation expense related to unvested RSUs was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20200930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_pn3n3" title="Unrecognized compensation expense related to unvested stock options granted under the plan">1,610, which is expected to be recognized over a weighted-average period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--UnvestedRSUMember_zpLqGdQ6PPH9" title="Expense expected to recognize over the weighted-average remaining vesting period">0.42 years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three and nine months ended September 30, 2020 was $357 and $884, respectively. Warrants From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders, underwriters and other non-employees for services rendered or to be rendered in the future, or pursuant to settlement agreements. A summary of warrant activity for the nine months ended September 30, 2020 is as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares Subject to Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuzexwTDgLU6" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlEzWAqBb8F1" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zc8hHYbRvwp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zt9zn0agPFI8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUsSHADrlW21" title="Weighted average remaining contractual life of the outstanding warrants in years">3.78</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrants outstanding and exercisable as of September 30, 2020 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Expiration</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Warrant Series</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Date</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center" title="Issue Date">5/11/2015</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 18%; text-align: right" title="Warrants Outstanding">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 15%; text-align: right" title="Exercise Price">1.79</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: center" title="Expiration Date">5/11/2025</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement warrants</td><td> </td> <td style="text-align: center" title="Issue Date">8/16/2016</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center" title="Expiration Date">8/16/2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lender warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt" title="Issue Date">7/19/2017</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding">615,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">2.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: center" title="Expiration Date">7/19/2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Subsidiary Stock-Based Transactions Mayfield Pharmaceuticals, Inc. During the nine months ended September 30, 2020, Mayfield repurchased <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_z4v1jJrsf9ak" title="Stock issued during period, shares, acquisitions">650,000 shares of its common stock from Elle, for an aggregate purchase price of $<span id="xdx_90D_ecustom--AggregatePurchasePrice_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__dei--LegalEntityAxis__custom--EllePharmaceuticalLLCMember_pii" title="Aggregate purchase price">1. During the nine months ended September 30, 2020, Mayfield issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pii" title="Shares issued of restricted common stock, shares">475,000 shares of its restricted common stock, with a fair value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pn3n3" title="Fair value of restricted common stock issued">11, that vest upon various performance-based milestones and over a four-year service period to Mayfield’s Chief Executive Officer candidate. During the nine months ended September 30, 2020, the Company recognized $17 in stock-based compensation tied to the Mayfield stock options. During the nine months ended September 30, 2020, <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MayfieldPharmaceuticalsIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_pii" title="Shares issued of restricted common stock, shares">500,000 shares of Mayfield’s restricted common stock were forfeited by a consultant. Stock-Based Compensation Summary <p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zBJg8REU0Xz" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">740</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">252</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,612</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,158</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Directors - selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">225</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Consultants - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">403</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">2,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,558</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

30000

167000

253

750

3.04

69 2998

2998

3.04

3.20

8000

91987

2429

46762

2000000

342882

A summary of stock option activity under the Plans for the nine months ended September 30, 2020 is as follows: SCHEDULE OF STOCK OPTION PLAN ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of shares</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Remaining Contractual Life</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">Options outstanding - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z5g56Mx1TR29" style="width: 12%; text-align: right" title="Number of shares, Outstanding, Beginning balance">2,656,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zgrtLChgDJGd" style="width: 12%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Beginning balance">5.30</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Number of shares, Options granted">414,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options granted">6.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zXVtheveefm8" style="text-align: right" title="Number of shares, Options exercised">(3,748</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="text-align: right" title="Weighted Avg. Exercise Price, Options exercised">3.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Options cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zml4SfZnasO5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Options cancelled/forfeited">(14,369</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Avg. Exercise Price, Options cancelled/forfeited">17.42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Options outstanding - September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zYVAIR18Qzw" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Outstanding, Ending balance">3,053,066</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zW8sJPTV1Qp5" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, Ending balance">5.41</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zs9RmlJ68GGg" title="Weighted Avg. Remaining Contractual Life, Options outstanding">5.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zgQCuQ62DRn1" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options outstanding">3,608</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Options exercisable – September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z72YgmfIaCN9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options exercisable">1,855,150</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zHiEXOpdNiSk" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Exercisable Ending Balance">4.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zGiJAjJDsAga" title="Weighted Avg. Remaining Contractual Life, Options exercisable">5.38</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z33Cwt2oOSb2" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options exercisable">3,294</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">Options vested and expected to vest – September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_z677C03jDKni" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options vested and expected to vest">2,940,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zih8ASpNrTvj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Vested and expected to vest">5.34</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zWablAkrYGze" title="Weighted Avg. Remaining Contractual Life, Options vested and expected to vest">5.93</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20200101__20200930__us-gaap--AwardTypeAxis__custom--StockOptionPlanOneMember_zXEgXA4KDIMd" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Options vested and expected to vest">3,605</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2656683

5.30

414500

6.44

3748

3.06

14369

17.42

3053066

5.41

P5Y11M19D

3608000

1855150

4.45

P5Y4M17D

3294000

2940527

5.34

P5Y11M4D

3605000

5.59

P10Y

Vesting terms for options granted to employees and consultants during the nine months ended September 30, 2020 generally included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; and 100% of the shares subject to the option vest on a quarterly basis in equal installments over three years. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plans) and in the event of certain modifications to the option award agreement.

600000

7.87

9 15

P5Y

1876000

0.70

0.0040

0.10

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees: SCHEDULE OF FAIR VALUE ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Weighted-average fair value of options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_pii" title="Weighted-average fair value of options granted">3.86</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected terms (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MinimumMember_ziN3DsiJ5wig" title="Expected terms (in years)">0.5 – <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember__srt--RangeAxis__srt--MaximumMember_zFnb9jTmQ5La" title="Expected terms (in years)">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z64v5AcTbyf7" title="Expected volatility, minimum">66.5% - <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zgDr1ApzWLh9" title="Expected volatility, maximum">71.4%</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zPRtiGANLAk3" title="Risk-free interest rate, minimum">0.34% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pii_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_z5SbuESlI1oi" title="Risk-free interest rate, maximum">1.64%</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_d0_uPercent_c20200101__20200930__us-gaap--AwardTypeAxis__custom--OptionsEmployeesMember_zOfFiHwX4pg5" title="Dividend yield">-</td><td style="text-align: left"> </td></tr> </table>

3.86

P0Y6M

P6Y1M9D

0.665

0.714

0.0034

0.0164

-0

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zxKzIp82N8hk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes information about stock options outstanding and exercisable at September 30, 2020: SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="4" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center">Weighted </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center">Average</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Weighted </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Weighted </td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center">Remaining </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Average</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: center"> </td> <td style="text-align: center">Number </td><td style="text-align: center"> </td> <td style="text-align: center">Contractual </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Exercise</td><td style="text-align: center"> </td> <td style="text-align: center">Number</td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td style="text-align: center">Exercise</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; text-align: left">Range of Exercise Prices</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Life in Years</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Exercisable</td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; text-align: left">$<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pii_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zwYgk4vLbwCi" title="Range of Exercise Prices, minimum">1.47 - $<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Range of Exercise Prices, maximum">2.60</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number of Options Outstanding">778,690</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zzWuIDZG8am5" title="Weighted Average Remaining Contractual Life in Years">5.90</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_zBz5Uaz7DNZi" title="Weighted Average Exercise Price">2.05</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Number Exercisable">728,938</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeOneMember_pii" title="Weighted Average Exercisable Exercise Price">2.07</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, minimum">2.76 - $<span id="xdx_90F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Range of Exercise Prices, maximum">4.66</td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number of Options Outstanding">531,785</td><td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zgk6lG6U6uB8" title="Weighted Average Remaining Contractual Life in Years">5.95</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_zq38Mb9apaQd" title="Weighted Average Exercise Price">3.98</td><td> </td> <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Number Exercisable">453,157</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeTwoMember_pii" title="Weighted Average Exercisable Exercise Price">3.98</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, minimum">5.49 - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Range of Exercise Prices, maximum">6.36</td><td> </td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Number of Options Outstanding">496,350</td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zHC4Ww9zVC3b" title="Weighted Average Remaining Contractual Life in Years">7.47</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_zcxAyl2J4Qmk" title="Weighted Average Exercise Price">6.10</td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Number Exercisable">263,814</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeThreeMember_pii" title="Weighted Average Exercisable Exercise Price">6.12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$<span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, minimum">6.64 - $<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Range of Exercise Prices, maximum">8.99</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Number of Options Outstanding">1,246,241</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zCkNtCNvCqY4" title="Weighted Average Remaining Contractual Life in Years">5.42</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_zAQxHsyxuDp1" title="Weighted Average Exercise Price">7.85</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Number Exercisable">409,241</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--RangeFourMember_pii" title="Weighted Average Exercisable Exercise Price">8.13</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left">$1.47 - $8.99</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,053,066</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20200101__20200930_zgyhtu30kdQd" title="Weighted Average Remaining Contractual Life in Years">5.97</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pii_c20200930_z2ClVLEek593" title="Weighted Average Exercise Price">5.41</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,855,150</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_c20200930_pii" title="Weighted Average Exercisable Exercise Price">4.45</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1.47

2.60

778690

P5Y10M24D

2.05

728938

2.07

2.76

4.66

531785

P5Y11M12D

3.98

453157

3.98

5.49

6.36

496350

P7Y5M19D

6.10

263814

6.12

6.64

8.99

1246241

P5Y5M1D

7.85

409241

8.13

1.47

8.99

3053066

P5Y11M19D

5.41

1855150

4.45

6021000

P4Y10D

559000

1094000

68024

400000

10000

39000

12500

72000

161000

1025000

A summary of the Company’s RSU activity and related information for the nine months ended September 30, 2020 is as follows: SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">RSUs unvested - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDUoSybrnu65" style="width: 16%; text-align: right" title="Number of RSUs unvested, Outstanding, Beginning balance">1,411,930</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmZr2pttm21i" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">2.76</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">RSUs granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Number of RSUs granted">251,524</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs granted">6.11</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">RSUs vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pii_di_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4IyVH2TMkbd" style="text-align: right" title="Number of RSUs vested">(49,190</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVfgw0ZcqO7h" style="text-align: right" title="Weighted Average Grant Date Fair Value, RSUs vested">6.61</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFA46lSw1EV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of RSUs cancelled/forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">RSUs unvested at September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgytN8YKcd9k" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of RSUs unvested, Outstanding, Ending balance">1,614,264</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pii_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_za9muqVwTpa2" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">3.16</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1411930

2.76

251524

6.11

49190

6.61

1614264

3.16

1610000

P0Y5M1D

357000

884000

A summary of warrant activity for the nine months ended September 30, 2020 is as follows: SCHEDULE OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 100%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Shares Subject to Warrants Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants outstanding - January 1, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zuzexwTDgLU6" style="width: 16%; text-align: right" title="Number of Shares Warrants Outstanding, beginning balance">780,386</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice1_iS_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlEzWAqBb8F1" style="width: 16%; text-align: right" title="Weighted Avg. Exercise Price, Outstanding, beginning balance">2.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="text-align: right" title="Number of Shares Warrants Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares Warrants Outstanding, Expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber_iE_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zc8hHYbRvwp8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares Warrants Outstanding and Exercisable, ending balance">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingAndExercisableWeightedAverageExercisePrice1_iE_pii_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zt9zn0agPFI8" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants in years - September 30, 2020</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average remaining contractual life of the outstanding warrants in years"><span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zUsSHADrlW21" title="Weighted average remaining contractual life of the outstanding warrants in years">3.78</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

780386

2.12 780386 2.12 P3Y9M10D Warrants outstanding and exercisable as of September 30, 2020 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Expiration</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid">Warrant Series</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Issue Date</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Date</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left">Lender warrants</td><td style="width: 2%"> </td> <td style="width: 20%; text-align: center" title="Issue Date">5/11/2015</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 18%; text-align: right" title="Warrants Outstanding">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsMember_pii" style="width: 15%; text-align: right" title="Exercise Price">1.79</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: center" title="Expiration Date">5/11/2025</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Settlement warrants</td><td> </td> <td style="text-align: center" title="Issue Date">8/16/2016</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Warrants Outstanding">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SettlementWarrantsMember_pii" style="text-align: right" title="Exercise Price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center" title="Expiration Date">8/16/2021</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Lender warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt" title="Issue Date">7/19/2017</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Outstanding">615,386</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LenderWarrantsOneMember_pii" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">2.08</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: center" title="Expiration Date">7/19/2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_c20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants Outstanding">780,386</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pii" style="padding-bottom: 2.5pt; text-align: right" title="Exercise Price">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2015-05-11

125000

1.79

2025-05-11 2016-08-16

40000

3.75

2021-08-16 2017-07-19

615386

2.08

2024-07-19

780386

2.12

650000

475000

11000

17000

500000

<p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zBJg8REU0Xz" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows: SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td><td> </td> <td colspan="6" style="text-align: center">For the</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2020</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2019</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Employees - selling, general and administrative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">740</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">252</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,612</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930__srt--TitleOfIndividualAxis__custom--EmployeesMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="width: 12%; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,158</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Directors - selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="text-align: right" title="Stock based compensation related to equity instruments granted to related parties">225</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Consultants - selling, general and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">76</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">96</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--IncomeStatementLocationAxis__custom--SellingGeneralAndAdministrativeMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200701__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">917</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">403</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">2,078</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock based compensation related to equity instruments granted to related parties">1,558</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

740000

252000

1612000

1158000

177000

75000

370000

225000

76000

96000

175000

917000

403000

2078000

1558000

NOTE 14. COMMITMENTS AND CONTINGENCIES Novel Drug Solutions et al. In April 2018, Novel Drug Solutions, LLC and Eyecare Northwest, PA (collectively “NDS”) filed a lawsuit against the Company in the U.S. District Court of Delaware asserting claims for breach of contract. The claims stem from an asset purchase agreement between the Company and NDS entered into in 2013. In July 2019, NDS filed a second amended complaint which added a claim related to its purported termination of the APA. In October 2019, NDS voluntarily dismissed all claims related to breach of contract, leaving only claims related to the scope of the post-termination obligations to be litigated. On October 29, 2020, at a hearing on the various dispositive motions before it, the Court found that there were triable issues of fact and reopened discovery for limited purposes. NDS is seeking unspecified damages, interest, attorney’s fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation and it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock. Product and Professional Liability Product and professional liability litigation represents an inherent risk to all firms in the pharmaceutical and pharmacy industry. We utilize traditional third-party insurance policies with regard to our product and professional liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written. John Erick et al. In January 2018, John Erick and Deborah Ferrell, successors-in-interest and heirs of Jade Erick, (collectively “Erick”) filed a lawsuit in the San Diego County Superior against Kim Kelly, ND, MPH asserting claims related to the death of Jade Erick. In April 2018, Erick filed an amendment to the lawsuit, naming the Company as a co-defendant. In September 2018, co-defendant Dr. Kelly filed a cross-complaint against the Company and various entities affiliated with Spectrum Laboratory Products, Inc., Spectrum Chemical Manufacturing Corp. and Spectrum Pharmacy Products, Inc. (collectively “Spectrum”). The cross-complaint seeks indemnity and contribution from the Company and Spectrum. The Company answered the claims filed by Dr. Kelly in October 2018. The case is currently in the discovery phase and the Company’s motion for summary adjudication is pending before the Court. Erick is seeking unspecified damages, interest, attorney’s fees and other costs. The Company believes the claims are meritless and has previously and will continue to dispute all claims asserted against it and intends to vigorously defend against these allegations. Nonetheless, the Company cannot predict the eventual outcome of this litigation, it could result in substantial costs, losses and a diversion of management’s resources and attention, which could harm the Company’s business and the value of its common stock. General and Other In the ordinary course of business, the Company may face various claims brought by third parties and it may, from time to time, make claims or take legal actions to assert its rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Indemnities In addition to the indemnification provisions contained in the Company’s governing documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets. Klarity License Agreement – Related Party The Company entered into a license agreement in April 2017 and as amended in April 2018, (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity used to protect and rehabilitate the ocular surface (the “Klarity Product”). <span id="xdx_90D_ecustom--RoyaltyPaymentDescription_c20170401__20170430__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description">Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn3n3_c20170401__20170430__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zwQvPOjHmeEj" title="Royalty expense">50 upon execution of the Klarity License Agreement, (ii) a second payment of $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">50 following the first $<span id="xdx_901_eus-gaap--RoyaltyExpense_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">50 in net sales of the Klarity Product; and (iii) a final payment of $<span id="xdx_906_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--SecondPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Sales revenue net">50 following the first $<span id="xdx_909_ecustom--NetSalesRevenue_c20170401__20170430__srt--StatementScenarioAxis__custom--FinalPaymentMember__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Sales revenue net">100 in net sales of the Klarity Product. All of the above referenced milestone payments are payable at the Company’s election in cash or shares of the Company’s restricted common stock. Payments totaling $<span id="xdx_90F_ecustom--MilestonePaymentInCash_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">0 and $<span id="xdx_909_ecustom--MilestonePaymentInCash_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">55 were made during the three and nine months ended September 30, 2020, respectively. Royalty expense of $<span id="xdx_907_eus-gaap--RoyaltyExpense_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">38 and $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--KlarityLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">94 was incurred during the three and nine months ended September 30, 2020, respectively, is included in accounts payable and is due to Dr. Lindstrom at September 30, 2020. Injectable Asset Purchase Agreement – Related Party In December 2019, the Company entered into an asset purchase agreement (the “Lindstrom APA”) with Dr. Lindstrom, a member of its Board of Directors. Pursuant to the terms of the Lindstrom APA, the Company acquired certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license an ophthalmic injectable product (the “Lindstrom Product”). Under the terms of the Lindstrom APA, <span id="xdx_906_ecustom--RoyaltyPaymentDescription_c20191201__20191231__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description">the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including an initial payment of $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20191201__20191231__srt--StatementScenarioAxis__custom--InitialPaymentMember__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">33 upon execution of the Lindstrom APA. Dr. Lindstrom was paid $<span id="xdx_906_ecustom--MilestonePaymentInCash_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">0 and $<span id="xdx_90F_ecustom--MilestonePaymentInCash_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Milestone payment in cash">7 in cash during the three and nine months ended September 30, 2020, respectively, and an additional $48 was payable to Dr. Lindstrom at September 30, 2020. The Company incurred royalty expense of $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">6 and $<span id="xdx_907_eus-gaap--RoyaltyExpense_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--InjectableAssetPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_pn3n3" title="Royalty Expense">48 related to the Lindstrom APA during the three and nine months ended September 30, 2020, respectively. Eyepoint Commercial Alliance Agreement In August 2020, the Company, through its wholly-owned subsidiary ImprimisRx, LLC, entered into a Commercial Alliance Agreement (the “Dexycu Agreement”) with Eyepoint Pharmaceuticals, Inc. (“Eyepoint”), pursuant to which Eyepoint granted the Company the non-exclusive right to co-promote DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the United States. Pursuant to the Dexycu Agreement, Eyepoint will pay the Company a fee calculated based on the quarterly sales of DEXCYU in excess of predefined volumes to specific customers of the Company in the U.S. Under the terms of the Dexycu Agreement, the Company shall use commercially reasonable efforts to promote and market DEXCYU in the U.S. Subject to early termination, the Dexycu Agreement expires on August 1, 2025, subject to specified notice periods and specified limitations, either party may terminate the Dexycu Agreement in the event of (i) uncured material breach by the other party or (ii) if DEXCYU ceases to have “pass-through” payment status. In addition, subject to certain limitations, the Company may terminate the Dexycu Agreement (i) for convenience subject to an extended specified notice period or (ii) in the event Eyepoint undergoes a change of control. Eyepoint may terminate the Dexycu Agreement, subject to specified notice periods and specified limitations, if the Company fails to achieve certain minimum sales levels during specified periods. During the three and nine months ended September 30, 2020, the Company recorded $7 in commission revenues related to the Dexycu Agreement. Sales and Marketing Agreements The Company has entered various sales and marketing agreements with certain organizations, to provide exclusive sales and marketing representation services to Harrow in select geographies in the U.S., in connection with our ophthalmic compounded formulations. Under the terms of the sales and marketing agreements, <span id="xdx_905_ecustom--RoyaltyPaymentDescription_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember" title="Royalty payment description">the Company is required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts. In addition, the Company is required to issue shares of the Company’s restricted common stock to certain organizations if net sales in the assigned territory reach certain future milestone levels by the end of their terms, as applicable. Commission expenses of $<span id="xdx_908_eus-gaap--SalesCommissionsAndFees_pn3n3_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z1V2BoGgeog8" title="Sales commissions and fees">741 and $<span id="xdx_90D_eus-gaap--SalesCommissionsAndFees_pn3n3_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zfgf4stCYPoi" title="Sales commissions and fees">1,745 were incurred under these agreements during the three and nine months ended September 30, 2020, respectively, of which $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200701__20200930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_z1jmoZjnP6k4" title="Stock based compensation related to equity instruments granted to related parties">0 and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200930__us-gaap--TypeOfArrangementAxis__custom--SalesAndMarketingAgreementsMember__srt--TitleOfIndividualAxis__custom--RichardLLindstromMDMember_zYA6jRemMVph" title="Stock based compensation related to equity instruments granted to related parties">83 were stock-based payments. Asset Purchase, License and Related Agreements The Company has acquired and sourced intellectual property rights related to certain proprietary innovations from certain inventors and related parties (the “Inventors”) through multiple asset purchase agreements, license agreements, strategic agreements and commission agreements. In general, these agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. Royalty expenses of $159 and $420 and $207 and $672 were incurred under these agreements for the three and nine months ended September 30, 2020 and 2019, respectively, and $590 and $207 are included in accounts payable at September 30, 2020 and 2019, respectively.

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.

50000

50000 100000 0 55000

38000

94000

the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold.

33000

0 7000 48000

6000

48000

August 1, 2025

7000

the Company is required to make commission payments equal to 10% to 14% of net sales for products above and beyond the initial existing sales amounts.

741000

1745000

83000

159000

420000

207000

672000

590000

207000

NOTE 15. SEGMENT INFORMATION AND CONCENTRATIONS Management evaluates performance of the Company based on operating segments. Segment performance for its two operating segments is based on segment contribution. The Company’s reportable segments consist of (i) its commercial stage pharmaceutical compounding business (Pharmaceutical Compounding), generally including the operations of the ImprimisRx business; and (ii) its start-up operations associated with pharmaceutical drug development business (Pharmaceutical Drug Development). Segment contribution for the segments represents net revenues less cost of sales, research and development, selling and marketing expenses, and select general and administrative expenses. The Company does not evaluate the following items at the segment level: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Selling, general and administrative expenses that result from shared infrastructure, including certain expenses associated with legal matters, public company costs (e.g. investor relations), board of directors and principal executive officers and other like shared expenses.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Operating expenses within selling, general and administrative expenses that result from the impact of corporate initiatives. Corporate initiatives primarily include integration, restructuring, acquisition and other shared costs.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Other select revenues and operating expenses including R&D expenses, amortization, and asset sales and impairments, net as not all such information has been accounted for at the segment level, or such information has not been used by all segments.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total assets including capital expenditures.</td></tr> </table> The Company defines segment net revenues as pharmaceutical compounded drug sales, licenses and other revenue derived from related agreements. Cost of sales within segment contribution includes direct and indirect costs to manufacture formulations and sell products, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs, manufacturing equipment and tenant improvements depreciation, the write-off of obsolete inventory and other related expenses. Selling, general and administrative expenses consist mainly of personnel-related costs, marketing and promotion costs, distribution costs, professional service costs, insurance, depreciation, facilities costs, transaction costs, and professional services costs which are general in nature and attributable to the segment. Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and nine months ended September 30, 2020: SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30, 2020</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">14,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">14,399</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zlty3U1YJgu6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,696</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zFrw5brbYOsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zifCry6bhbq4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,696</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">10,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GrossProfit_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">10,703</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,893</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,937</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">94</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">22</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">116</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--SegmentContribution_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,716</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--SegmentContribution_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(66</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--SegmentContribution_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,650</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,460</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">554</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AdjustmentForAmortization_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Asset sales and impairments, net</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating income</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">1,597</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">For the Nine Months ended September 30, 2020</td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center">Pharmaceutical</td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center">Pharmaceutical</td><td style="font-size: 10pt"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">34,276</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">34,276</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zbCJZ4PXZvB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(10,526</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zcRxHuv91Nmf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zw75YXoOpy04" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(10,526</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">23,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GrossProfit_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">23,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,262</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">634</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">79</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">713</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--SegmentContribution_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,985</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SegmentContribution_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(210</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SegmentContribution_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,775</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">6,417</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">1,109</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AdjustmentForAmortization_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">127</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Asset sales and impairments, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">363</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(2,241</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30, 2019</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">12,755</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">12,755</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zA9YIW8uwhs8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,061</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zIbW2dXHHryl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1O2J4zXFQ0k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,061</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GrossProfit_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">8,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--GrossProfit_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">8,694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,244</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,288</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">193</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">96</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">289</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SegmentContribution_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">2,257</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SegmentContribution_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(140</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--SegmentContribution_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">2,117</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,280</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">155</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AdjustmentForAmortization_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Asset sales and impairments, net</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">4,040</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating loss</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(4,398</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine Months Ended September 30, 2019</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">38,561</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">38,561</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zpr8FhTCS2Na" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(13,184</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zWOtda4e8gR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDPQY8gkihG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(13,184</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GrossProfit_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">25,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--GrossProfit_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">25,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,763</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,893</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">851</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">359</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">1,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--SegmentContribution_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">6,763</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--SegmentContribution_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(489</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--SegmentContribution_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">6,274</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">7,341</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">449</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AdjustmentForAmortization_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">165</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Asset sales and impairments, net</td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">4,040</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating loss</td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(5,721</td><td style="text-align: left">)</td></tr> </table> The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues are attributed to the U.S. All long-lived assets at September 30, 2020 and December 31, 2019 are located in the U.S. The Company sells its compounded formulations to a large number of customers. No customer accounted for more than 10% of the Company’s total pharmacy sales for the three and nine months ended September 30, 2020 and 2019. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 76% and 72% of active pharmaceutical ingredient purchases during the three and nine months ended September 30, 2020, respectively, and 69% and 66% during the three and nine months ended September 30, 2019, respectively.

two operating segments

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three and nine months ended September 30, 2020: SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30, 2020</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">14,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">14,399</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zlty3U1YJgu6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,696</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zFrw5brbYOsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zifCry6bhbq4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(3,696</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">10,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--GrossProfit_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--GrossProfit_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">10,703</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,893</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">5,937</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">94</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">22</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">116</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--SegmentContribution_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,716</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--SegmentContribution_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(66</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--SegmentContribution_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">4,650</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,460</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">554</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--AdjustmentForAmortization_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">39</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Asset sales and impairments, net</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating income</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingIncomeLoss_c20200701__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">1,597</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">For the Nine Months ended September 30, 2020</td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center">Pharmaceutical</td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center">Pharmaceutical</td><td style="font-size: 10pt"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">34,276</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">34,276</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zbCJZ4PXZvB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(10,526</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zcRxHuv91Nmf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zw75YXoOpy04" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(10,526</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">23,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--GrossProfit_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--GrossProfit_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">23,750</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">131</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SellingGeneralAndAdministrativeExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,262</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">634</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">79</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">713</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--SegmentContribution_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,985</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--SegmentContribution_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(210</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SegmentContribution_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">5,775</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">6,417</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">1,109</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt">Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AdjustmentForAmortization_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">127</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Asset sales and impairments, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">363</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20200101__20200930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(2,241</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Three Months Ended September 30, 2019</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">12,755</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">12,755</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zA9YIW8uwhs8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,061</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zIbW2dXHHryl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z1O2J4zXFQ0k" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(4,061</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GrossProfit_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">8,694</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--GrossProfit_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--GrossProfit_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">8,694</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,244</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">6,288</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">193</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ResearchAndDevelopmentExpense_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">96</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ResearchAndDevelopmentExpense_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">289</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SegmentContribution_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">2,257</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--SegmentContribution_c20190701__20190930__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(140</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--SegmentContribution_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">2,117</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">2,280</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingIncomeLoss_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">155</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AdjustmentForAmortization_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Asset sales and impairments, net</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">4,040</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating loss</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingIncomeLoss_c20190701__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(4,398</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine Months Ended September 30, 2019</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Pharmaceutical</td><td style="text-align: center"> </td><td style="text-align: center; font-size: 12pt"> </td> <td colspan="2" style="text-align: center; font-size: 12pt"> </td><td style="text-align: center; font-size: 12pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; font-size: 12pt"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Compounding</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Drug Development</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">38,561</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="width: 16%; text-align: right" title="Total Revenues">38,561</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cost of sales</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_zpr8FhTCS2Na" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(13,184</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_zWOtda4e8gR6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--CostOfGoodsAndServicesSold_iN_pn3n3_di_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zDPQY8gkihG" style="border-bottom: Black 1.5pt solid; text-align: right" title="Cost of sales">(13,184</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--GrossProfit_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Gross profit">25,377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--GrossProfit_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Gross profit">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--GrossProfit_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Gross profit">25,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating expenses:</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Selling, general and administrative</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,763</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="text-align: right" title="Selling, general and administrative">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SellingGeneralAndAdministrativeExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Selling, general and administrative">17,893</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">851</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">359</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ResearchAndDevelopmentExpense_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Research and development">1,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Segment contribution</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--SegmentContribution_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalCompoundingMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">6,763</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--SegmentContribution_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--PharmaceuticalDrugDevelopmentMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">(489</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--SegmentContribution_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Segment contribution">6,274</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Corporate</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--OperatingIncomeLoss_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_pn3n3" style="text-align: right" title="Operating income (loss)">7,341</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--OperatingIncomeLoss_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pn3n3" style="text-align: right" title="Operating income (loss)">449</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Amortization</td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--AdjustmentForAmortization_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="text-align: right" title="Amortization">165</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Asset sales and impairments, net</td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ImpairmentAndDisposalOfLonglivedAssets_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset sales and impairments, net">4,040</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating loss</td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td style="font-size: 12pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; font-size: 12pt; text-align: right"> </td><td style="font-size: 12pt; text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--OperatingIncomeLoss_c20190101__20190930__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_pn3n3" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating income (loss)">(5,721</td><td style="text-align: left">)</td></tr> </table>

14399000

3696000

10703000

5893000

44000

5937000

94000

22000

116000

4716000 -66000 4650000

2460000

554000

39000

1597000

34276000

10526000

23750000

17131000

131000

17262000

634000

79000

713000

5985000 -210000 5775000

6417000

1109000

127000

363000

-2241000

12755000

4061000

8694000

6244000

44000

6288000

193000

96000

289000

2257000 -140000 2117000

2280000

155000

40000

4040000

-4398000

38561000

13184000

25377000

17763000

130000

17893000

851000

359000

1210000

6763000 -489000 6274000

7341000

449000

165000

4040000

-5721000

0.10

0.76

0.72

0.69

0.66

NOTE 16. SUBSEQUENT EVENTS The Company has performed an evaluation of events occurring subsequent to September 30, 2020 through the filing date of this Quarterly Report. Based on its evaluation, no events other than those described herein need to be disclosed. In October 2020, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201031__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zI6Z3pfjLpAj" title="Stock issued during period, shares, new issues">93,798 shares of its common stock underlying RSUs held by a director that resigned. The RSUs had previously vested during the nine months ended September 30, 2020, but the issuance and delivery of the shares were deferred until the director resigned.

93798